<?xml version="1.0" ?>
<tei>
	<teiHeader>
		<fileDesc xml:id="0"/>
	</teiHeader>
	<text xml:lang="en">
			<titlePage>Please cite this paper as: <lb/>de Lagasnerie, G. et al. (2015), &quot; Tapering payments in <lb/>hospitals: Experiences in OECD countries &quot; , OECD Health <lb/>Working Papers, No. 78, OECD Publishing, Paris. <lb/>http://dx.doi.org/10.1787/5js4h5rlkxxr-en <lb/>OECD Health Working Papers No. 78 <lb/>Tapering payments in <lb/>hospitals <lb/>EXPERIENCES IN OECD COUNTRIES <lb/>Grégoire de Lagasnerie, Valérie Paris, <lb/>Michael Mueller, Ankit Kumar <lb/>JEL Classification: D22, D24, H51, I18, L84, L88 <lb/>Unclassified <lb/>DELSA/HEA/WD/HWP(2015)1 <lb/>Organisation de Coopération et de Développement Économiques <lb/>Organisation for Economic Co-operation and Development <lb/>27-Mar-2015 <lb/>___________________________________________________________________________________________ <lb/>_____________ <lb/>English text only <lb/>DIRECTORATE FOR EMPLOYMENT, LABOUR AND SOCIAL AFFAIRS <lb/>HEALTH COMMITTEE <lb/>Health Working Papers <lb/>OECD Health Working Paper No. 78 <lb/>TAPERING PAYMENTS IN HOSPITALS --EXPERIENCES IN OECD COUNTRIES <lb/>Grégoire de Lagasnerie, Valérie Paris, Michael Mueller, Ankit Kumar <lb/>JEL classification: D22, D24, I18, L84, L88, H51 <lb/>Authorised for publication by Stefano Scarpetta, Director, Directorate for Employment, Labour and <lb/>Social Affairs <lb/>All Health Working papers are now available through the OECD&apos;s Internet Website at <lb/>http://www.oecd.org/els/health-systems/health-working-papers.htm <lb/>JT03373318 <lb/>Complete document available on OLIS in its original format <lb/>This document and any map included herein are without prejudice to the status of or sovereignty over any territory, to the delimitation of <lb/>international frontiers and boundaries and to the name of any territory, city or area. <lb/>DELSA/HEA/WD/HWP(2015)1 <lb/>Unclassified <lb/>English <lb/>text <lb/>only <lb/></titlePage>

			<front>DELSA/HEA/WD/HWP(2015)1 <lb/>2 <lb/>DIRECTORATE FOR EMPLOYMENT, LABOUR AND SOCIAL AFFAIRS <lb/>www.oecd.org/els <lb/>OECD HEALTH WORKING PAPERS <lb/>http://www.oecd.org/els/health-systems/health-working-papers.htm <lb/>OECD Working Papers should not be reported as representing the official views of the OECD or of its <lb/>member countries. The opinions expressed and arguments employed are those of the author(s). <lb/>Working Papers describe preliminary results or research in progress by the author(s) and are <lb/>published to stimulate discussion on a broad range of issues on which the OECD works. Comments on <lb/>Working Papers are welcomed, and may be sent to the Directorate for Employment, Labour and Social <lb/>Affairs OECD, 2 rue André-Pascal, 75775 Paris Cedex 16, France. <lb/>This series is designed to make available to a wider readership selected health studies prepared for use <lb/>within the OECD. Authorship is usually collective, but principal writers are named. The papers are <lb/>generally available only in their original language – English or French – with a summary in the other. <lb/>The statistical data for Israel are supplied by and under the responsibility of the relevant Israeli <lb/>authorities. The use of such data by the OECD is without prejudice to the status of the Golan Heights, East <lb/>Jerusalem and Israeli settlements in the West Bank under the terms of international law. <lb/>Applications for permission to reproduce or translate <lb/>all or part of this material should be made to: <lb/>Head of Publications Service <lb/>OECD <lb/>2, rue André-Pascal <lb/>75775 Paris, CEDEX 16 <lb/>France <lb/>Copyright OECD 2015 <lb/></front>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>3 <lb/></page>

			<front>ACKNOWLEDGEMENTS <lb/>This study was carried out thanks to a voluntary contribution from France and written up by members <lb/>of the Health Division of the OECD. France is thus often prominent in the qualitative and quantitative <lb/>analyses presented in this document. The opinions expressed in it are those of the authors and do not <lb/>necessarily reflect those of the OECD or the French Government. The various figures and tables are taken <lb/>from OECD Health Statistics 2013 unless stated otherwise. The authors would like to thank the following <lb/>for supporting this project and for their comments: Agence Technique de l&apos;Information sur <lb/>l&apos;Hospitalisation (ATIH), especially Véronique Sauvadet, Nathalie Rigollot and Florence Pinelli, also the <lb/>Direction Générale de l&apos;Offre de Soins, especially Adeline Townsend and Adrien Dozol. The authors are <lb/>also grateful to those who helped them in the countries used for the case studies: Lenka Poliaková, Jan <lb/>Alexa, Dr. Leon Levi, Eli Cohen, Shlomit Krapivka, Yonatan Green, Robert Murray, Graham Atkinson, <lb/>Donna Kinzer, Jack Keane, Jack Cook, Sue Calikoglu, Jerry Schmidth, Ferdinand Rau, Marc Schreiner, <lb/>Dr. Roland Laufer, Dr. Christian Jaeger, Johannes Wolff, Uwe Klein-Hitpaß, Dr. David Scheller-Kreinsen, <lb/>Dr. Alexander Geissler and Dr. Wilm Quentin. Special thanks are also due, within the OECD, to Michael <lb/>Schoenstein for his vital contribution to the case study on Germany and to David Morgan for his advice <lb/>and comments. <lb/></front>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>4 <lb/></page>

			<body>ABSTRACT <lb/>This study covers &quot; tapering scale &quot; mechanism in hospital payments, i.e. mechanisms linking unit <lb/>prices to the volume of services produced. This paper begins with an overview of hospital services and <lb/>hospital payment methods in OECD countries, focusing more specifically on DRG-based payment. It then <lb/>reviews studies published on economies of scales in hospitals, which is the economic rationale justifying <lb/>tapering payments. Thereafter, four case studies from Germany, the US State of Maryland, the Czech <lb/>Republic and Israel offer a detailed insight into the practicalities of introducing this method of controlling <lb/>hospital volumes and the impacts it has had. <lb/>RÉSUMÉ <lb/>Ce rapport porte sur les politiques de dégressivité tarifaire appliquées au paiement des hôpitaux, c&apos;est-<lb/>à-dire les mécanismes liant les prix unitaires des services hospitaliers au volume de soins produits. Ce <lb/>document de travail dresse tout d&apos;abord un panorama de l&apos;offre hospitalière et des modes de paiement des <lb/>hôpitaux au sein des pays de l&apos;OCDE en étudiant plus spécifiquement le paiement à l&apos;activité. Il présente <lb/>ensuite une revue des études portant sur les économies d&apos;échelle dans le secteur hospitalier, justification <lb/>principale de la diminution des tarifs au-delà d&apos;un seuil de production. Enfin, quatre études de cas en <lb/>Allemagne, l&apos;État du Maryland, la République tchèque et Israël sont présentées afin d&apos;étudier finement les <lb/>modalités d&apos;instauration et l&apos;impact de ce mécanisme de contrôle des volumes hospitaliers. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>5 <lb/></page>

			<body>TABLE OF CONTENTS <lb/>ACKNOWLEDGEMENTS ............................................................................................................................ 3 <lb/>ABSTRACT .................................................................................................................................................... 4 <lb/>RÉSUMÉ ......................................................................................................................................................... 4 <lb/>EXECUTIVE SUMMARY AND MAIN CONCLUSIONS ........................................................................... 7 <lb/></body>

			<titlePage>INTRODUCTION ........................................................................................................................................... 8 <lb/>OVERVIEW OF HOSPITAL SECTOR AND PAYMENT METHODS IN OECD COUNTRIES .............. 9 <lb/>The share of hospital care costs in total health spending is falling, but still accounts for 29% of <lb/>expenditure in OECD countries ................................................................................................................... 9 <lb/>Hospital funding in OECD countries ......................................................................................................... 12 <lb/>Hospital costs are mainly financed by the public sector ........................................................................ 12 <lb/>Trend towards DRG-based payment in health insurance systems ......................................................... 15 <lb/>ECONOMIES OF SCALE IN HOSPITALS: A LITERATURE REVIEW ................................................. 21 <lb/>Accounting approach: identification of the proportion of fixed costs in hospital care production ............ 21 <lb/>Static approach: for some procedures, fixed costs represent the majority of production costs .............. 21 <lb/>Dynamic approach: semi-variable expenses must be taken into account when calculating the cost <lb/>structure of hospitals .............................................................................................................................. 23 <lb/>Literature review of the economic studies relating to the existence of economies of scale in hospitals ... 24 <lb/>Theoretical model and econometric models ........................................................................................... 24 <lb/>Data used in studies ................................................................................................................................ 25 <lb/>Results .................................................................................................................................................... 28 <lb/>EXPERIENCES OF TAPERING PAYMENT SCALES IN FOUR OECD COUNTRIES ......................... 30 <lb/>Germany ..................................................................................................................................................... 30 <lb/>Basic facts of health system ................................................................................................................... 30 <lb/>Hospitals ................................................................................................................................................. 30 <lb/>Hospital payments in Germany .............................................................................................................. 31 <lb/>The tapering system ............................................................................................................................... 32 <lb/>Maryland (United States) ........................................................................................................................... 37 <lb/>Basic facts of health system ................................................................................................................... 37 <lb/>Hospitals ................................................................................................................................................. 38 <lb/>Hospital payments in the State of Maryland .......................................................................................... 40 <lb/>Hospital revenue budgets ....................................................................................................................... 41 <lb/>Tapering payment or variable cost factor (VCF) in the State of Maryland ............................................ 42 <lb/>Czech Republic .......................................................................................................................................... 44 <lb/>Basic facts of the health system ............................................................................................................. 44 <lb/>Hospitals ................................................................................................................................................. 44 <lb/>Hospital payments in the Czech Republic .............................................................................................. 45 <lb/>The tapering payment system in the Czech Republic ............................................................................ 46 <lb/>Rationale of introduction ........................................................................................................................ 47 <lb/>Evaluation of effectiveness .................................................................................................................... 47 <lb/>Israel........................................................................................................................................................... 48 <lb/>Basic facts of health system ................................................................................................................... 48 <lb/>Hospital payments in Israel .................................................................................................................... 49 <lb/></titlePage>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>6 <lb/></page>

			<body>The tapering payment system in Israel ................................................................................................... 49 <lb/>Summary of tapering experiences .............................................................................................................. 52 <lb/>CONCLUSION ............................................................................................................................................. 57 <lb/>REFERENCES .............................................................................................................................................. 60 <lb/>ANNEX 1: DETAILED DESCRIPTION OF THE FEATURES OF DRG-BASED PAYMENT SYSTEMS <lb/>IN OECD COUNTRIES................................................................................................................................ 65 <lb/>ANNEX 2: SETTING THE POINT VALUE IN GERMANY ..................................................................... 70 <lb/>ANNEX 3: FORMULA FOR CALCULATING THE HOSPITAL&apos;S ACTIVITIES CAP AND REVENUE <lb/>IN THE CZECH REPUBLIC ........................................................................................................................ 72 <lb/>Tables <lb/>Table 1: Basic health care coverage in the OECD countries ..................................................................... 13 <lb/>Table 2: Main hospital payment method used by health insurance systems, by legal status of hospitals, in <lb/>2012 ........................................................................................................................................................... 18 <lb/>Table 3: Main method used to pay hospitals, by legal status, in 2012 in systems funded by taxation ...... 19 <lb/>Table 4: The different procedures analysed in the Health Benefit Basket project ..................................... 22 <lb/>Table 5: Description of data used when evaluating economies of scale in the hospital sector and cost <lb/>elasticity ..................................................................................................................................................... 27 <lb/>Table 6: Rate of growth in case mix between 2004 and 2014 ................................................................... 36 <lb/>Table 7: The tapering payment mechanism in Israel ................................................................................. 51 <lb/>Table 8: Summary ...................................................................................................................................... 54 <lb/>Table A.1: History and main characteristics of hospital stay classification systems introduced in selected <lb/>OECD countries ......................................................................................................................................... 66 <lb/>Table A.2: Inclusion of capital costs and training and teaching activities in DRG-based payments in the <lb/>OECD countries ......................................................................................................................................... 68 <lb/>Table A.3: Scope of DRG-based payment for certain health services in the OECD countries ................. 69 <lb/>Figures <lb/>Figure 1: Per capita spending on hospital inpatient care in 2011 (or nearest year) ................................... 10 <lb/>Figure 2: Current health expenditure by function of health care in 2011 (or nearest year) ....................... 11 <lb/>Figure 3: Average annual growth rates of health spending for selected functions, in real terms, OECD <lb/>average, 2008 to 2011 ................................................................................................................................ 12 <lb/>Figure 4: Structure of hospital cost funding in 2011 (or nearest year) ...................................................... 14 <lb/>Figure 5: Structure of public and private hospital funding in 2011 (or nearest year) ................................ 15 <lb/>Figure 6: Proportion accounted for by general expenses in four inpatient procedures in France and <lb/>averaged over nine OECD member countries ............................................................................................ 23 <lb/>Figure 7: Expenses per inpatient day for hospital services requiring at least one night as an inpatient in <lb/>Maryland and in the United States (2001-2011) ........................................................................................ 38 <lb/>Figure 8: Admissions per 1 000 population between 1999 and 2011 in the State of Maryland and in the <lb/>United States .............................................................................................................................................. 40 <lb/>Figure 9: Total case mix for care between 2007 and 2012 ........................................................................ 48 <lb/>Boxes <lb/>Box 1. Definition of main hospital payment systems ................................................................................ 16 <lb/>Box 2. Efficiency in the hospital sector, economies of scope and influence of hospitals&apos; status on costs 28 <lb/>Charts <lb/>Chart 1: Hospital payments in Germany .................................................................................................... 34 <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>7 <lb/></page>

			<body>EXECUTIVE SUMMARY AND MAIN CONCLUSIONS <lb/>1. <lb/>Against a background of increased pressure on public finances, the question of how to control <lb/>hospital spending, which is predominantly funded from public sources, is a major issue for OECD <lb/>countries. In 2011, hospital care accounted for 29% of all health spending, on average in OECD countries, <lb/>and for 2.6% of gross domestic product (GDP). In two-thirds of OECD countries, around 90% of these <lb/>costs are funded out of public finances. <lb/>2. <lb/>Payment systems are among the instruments available to public or private payers to regulate the <lb/>behaviour of health care providers and encourage certain structures to become more efficient and <lb/>productive. This study looks in depth into one mechanism used in hospital payments: the tapering payment, <lb/>by which the remuneration per hospital case is reduced beyond a volume threshold. Tapering payment is <lb/>based on the hypothesis that economies of scales exist in hospital production and generally aims to control <lb/>spending and/or discourage excessive volumes of care. This mechanism has been adopted in at least six <lb/>OECD countries. <lb/>3. <lb/>To provide the best possible picture of the challenges entailed in operating a tapering scale <lb/>mechanism, this paper begins with an overview of hospital services and hospital payment methods in <lb/>OECD countries, focusing more specifically on DRG-based payment, the framework within which <lb/>tapering payment most often operates. The study then sets out the economic rationale justifying the <lb/>tapering scale, drawing on a review of the literature on economies of scale within the hospital sector. <lb/>Thereafter, four case studies from Germany, the US State of Maryland, the Czech Republic and Israel offer <lb/>a detailed insight into the practicalities of introducing this mechanism for controlling hospital volumes and <lb/>the impacts it has had. The key findings of this report are the following: <lb/> Whereas global budgets are the predominant mode of payment for hospital services in tax-funded <lb/>national health systems, remuneration through DRGs is the main mode to pay for hospital <lb/>services in countries with social health insurance. Tapering payments is a tool most often used in <lb/>DRG-type systems. <lb/> Five health insurance systems – namely in Germany, the US State of Maryland, the Czech <lb/>Republic, Israel, and Hungary – and one tax-funded health system (Australia) have introduced <lb/>tapering payment. <lb/> Tapering payment is intended primarily to contain the growth of hospital costs by imposing <lb/>constraints on individual hospitals rather than on the hospital sector as a whole. <lb/> Tapering payment is justified by the existence of economies of scale, even if the empirical <lb/>evidence for such economies in the hospital sector is not used in setting activity thresholds or <lb/>rates of tapering payment where such mechanisms apply. <lb/> Tapering payment is applied uniformly to all hospital activities, with a few exceptions, but some <lb/>countries make adjustments to take into account the impact of new activities on hospital volume. <lb/> Given the moderate impact of tapering payment on hospital activities, some of the countries <lb/>studied are inclined to introduce more rigorous systems to contain spending growth. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>8 <lb/></page>

			<body>INTRODUCTION 1 <lb/>4. <lb/>The question of how to control hospital spending, which is mainly publicly funded, is a major <lb/>issue for OECD countries. In 2011, hospital care accounted, on average, for 29% of all health spending in <lb/>the OECD countries and 2.6% of gross domestic product (GDP). In two-thirds of the OECD countries, <lb/>over 90% of these costs are funded from public sources. <lb/>5. <lb/>Payment systems are just one of the instruments available to private or public payers to regulate <lb/>the behaviour of health care providers and encourage certain structures to become more efficient and <lb/>productive. OECD countries introduced DRG-based hospital payment systems for different reasons, <lb/>including increase efficiency in the use of resources in hospitals, contain hospital costs, increase <lb/>transparency, reduce waiting times, support patient choices and/or improve the quality of care. The tool to <lb/>achieve these objectives is prospective tariffs per case depending on the diagnosis and procedures <lb/>performed and irrespective of the actual costs incurred. These DRG-based payments serve as financial <lb/>incentives to hospitals to reduce costs per patient and average length of stay thus improving technical <lb/>efficiency. But payment via DRG also encourages hospitals to treat more patients and increase hospital <lb/>activity when marginal revenue is above the marginal cost per patient. Whether expenditure in hospitals <lb/>increases or decreases depends on which of the two contrary effects dominate: increasing the number of <lb/>cases or decreasing the number of services per case (Geissler et al. 2011). <lb/>6. <lb/>In order to contain the inflation of hospital activity under DRG-based payment systems and to <lb/>incentivize hospitals to perform only strictly necessary procedures, some OECD countries have reduced <lb/>the rate of remuneration (tariff) by which DRG-based payments are made above a defined volume of <lb/>production. The main reason to justify this payment reduction, a mechanism known as &quot; tapering payment &quot; , <lb/>is that -as in many alternative industries -economies of scale can be achieved in the production process of <lb/>hospital services. Economies of scale are achieved when the unit cost of production decreases when total <lb/>production increases. This concept is especially pertinent where production entails a significant level of <lb/>fixed costs. Whilst the nature of costs (fixed and variable) can vary over time, the structure of hospital <lb/>production has features which, in theory at least, justify the existence of economies of scale. Depreciation, <lb/>maintenance, and general logistics are fixed costs which are theoretically already fully taken into account <lb/>once a pre-defined level of production is attained. Above this threshold, reduced payments based on a <lb/>tapering scale then means that the hospital will only be reimbursed for the variable costs of the care it <lb/>delivers. <lb/>7. <lb/>For a full picture of the challenges entailed in operating a tapering scale mechanism, this paper <lb/>begins with an overview of hospital services and hospital payment methods across OECD countries, <lb/>focusing more specifically on DRG-based payment systems, the framework within which tapering payment <lb/>can be made operational. Our study then sets out the economic arguments for introducing the tapering <lb/>scale, drawing on a review of the literature on economies of scale within the hospital sector. Thereafter, <lb/>four case studies from Germany, the US State of Maryland, the Czech Republic and Israel are presented to <lb/>give detailed insights into the different approaches of introducing this mechanism, the national context of <lb/>the implementation, and the impacts it has had on controlling hospital volumes. <lb/></body>

			<note place="footnote">1 <lb/>This analysis was motivated by a request from the French Ministry of Health. In France, an overall health <lb/>spending ceiling is set annually by the parliament, which also defines an upper boundary for overall <lb/>hospital spending. Once this boundary is reached, the system reacts by automatically lowering the tariffs <lb/>for all DRGs (payment via DRG is the main mode of financing hospital activity) included in the catalogue <lb/>applicable to all hospitals by the same percentage. The French Ministry of Health has questioned whether <lb/>mechanisms exist in other countries to reduce DRG tariffs in a more discriminate way by targeting certain <lb/>DRGs or hospitals that are responsible for hospital overspending at an aggregate level. <lb/></note>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>9 <lb/></page>

			<body>OVERVIEW OF HOSPITAL SECTOR AND PAYMENT METHODS IN OECD COUNTRIES <lb/>8. <lb/>Against a background of increased pressure on public finances, the question of how to control <lb/>hospital spending is a major issue for policy makers in many OECD countries. Hospital care <lb/>2 accounts for <lb/>29% of total health spending on average across OECD countries. In some countries, such as France, <lb/>Greece and Austria, this share is more than a third. <lb/>9. <lb/>When it comes to reining in hospital spending, the mechanisms by which hospitals are paid can <lb/>play a pivotal role as they provide different financial incentives for actors in this sector. In OECD <lb/>countries, four main types of payment system are used to remunerate hospitals: DRG-based payment, <lb/>prospective global budgets, line-item budgeting and fee-for-service/payment for activity (see Box 1 for <lb/>definitions). The first section below describes the main features of the hospital sector in OECD countries <lb/>and shows the diversity of the contexts within which the various hospital payment systems operate. The <lb/>next sections presents how hospital care is financed and how hospital services are paid for. <lb/>The share of hospital care costs in total health spending is falling, but still accounts for 29% of <lb/>expenditure in OECD countries <lb/>10. <lb/>The following brief overview of hospital spending seeks to put the use of DRG-based payment <lb/>and payment reductions based on a tapering scale in OECD countries into a financial context. <lb/>11. <lb/>Spending on hospital care accounted, on average, for 2.6% of gross domestic product (GDP) in <lb/>OECD countries in 2011 (OECD Health Statistics, 2013) but differed widely across countries. The figure <lb/>was highest for France (4.2% of GDP), followed by Austria (3.6%) and Greece (3.4% of GDP). At the <lb/>other end of the scale, Chile devoted only 1% of its GDP to inpatient care. <lb/>12. <lb/>In a similar way, per capita spending on hospital care ranged from USD PPP 209 to 1 660 in <lb/>2011. It stood at USD PPP 1 482 in France which was about 50% above the OECD average of <lb/>USD PPP 973 (Figure 1) but still somewhat below the top spenders Norway (1 660 USD PPP), <lb/>Switzerland (1 561 USD PPP) and Austria (1 530 USD PPP). <lb/></body>

			<note place="footnote">2 <lb/>In this paper, &quot; hospital spending &quot; and &quot; hospital costs &quot; refer to cost of inpatient curative and rehabilitative <lb/>care including day cases. It does not include outpatient consultations. <lb/></note>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>10 <lb/></page>

			<body>Figure 1: Per capita spending on hospital inpatient care in 2011 (or nearest year) <lb/>* Data for 2010 <lb/>Source: OECD Health Statistics 2013 <lb/>13. <lb/>Spending on hospital and outpatient care makes up a significant proportion of overall health <lb/>spending in OECD countries. In 2011, together they accounted for about 62% of current health spending, <lb/>on average (Figure 2). A further 20% of health spending went on medical goods (mainly pharmaceuticals, <lb/>which were 17% of the total), 12% on long-term care and the remaining 6% on collective services, such as <lb/>public health programmes, preventive services and administration. <lb/>0 <lb/>200 <lb/>400 <lb/>600 <lb/>800 <lb/>1000 <lb/>1200 <lb/>1400 <lb/>1600 <lb/>1800 <lb/>USD <lb/>PPP <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>11 <lb/></page>

			<body>Figure 2: Current health expenditure by function of health care in 2011 (or nearest year) <lb/>* Inpatient curative and follow-up care and rehabilitation, including one-day stays. <lb/>** Includes domiciliary care and ancillary services. <lb/>1 In the USA, fees charged by independent doctors for inpatients are included in outpatient care. <lb/>Source: OECD Health Statistics 2013. <lb/>14. <lb/>Spending on inpatient care (including day care in hospitals) is the biggest cost component for a <lb/>number of countries, including France and Greece where it accounts for 37% of total spending – <lb/>8 percentage points more than the average for the OECD countries. <lb/>15. <lb/>On average, spending on inpatient care in OECD countries continued to grow in 2010 and 2011, <lb/>albeit at a markedly slower rate than in 2008 and 2009 (Figure 3). Many countries have taken measures to <lb/>rein in public spending in this area: cutting staff numbers, reducing salaries paid to health professionals and <lb/>fees paid to health care providers, and increasing the patient&apos;s out-of-pocket share -all in an attempt to <lb/>ease the pressure on budgets (Morgan and Astolfi, 2013). <lb/>37 37 36 35 32 32 32 31 31 30 30 30 30 29 29 29 29 28 28 27 27 26 26 25 25 22 20 18 <lb/>22 <lb/>27 28 28 <lb/>28 <lb/>33 35 34 36 <lb/>26 26 <lb/>36 <lb/>22 <lb/>30 33 31 33 <lb/>42 <lb/>34 35 <lb/>45 48 <lb/>38 <lb/>28 <lb/>33 <lb/>33 35 <lb/>51 <lb/>11 1 <lb/>15 <lb/>6 <lb/>9 <lb/>9 <lb/>4 <lb/>15 <lb/>4 21 <lb/>29 10 <lb/>24 12 <lb/>12 19 <lb/>24 8 <lb/>20 21 2 <lb/>8 <lb/>11 <lb/>4 <lb/>12 <lb/>0 <lb/>15 <lb/>6 <lb/>21 31 <lb/>17 <lb/>26 24 <lb/>22 24 <lb/>11 24 <lb/>17 <lb/>11 <lb/>17 15 20 <lb/>20 <lb/>18 <lb/>11 <lb/>16 11 12 <lb/>23 <lb/>15 <lb/>21 <lb/>37 <lb/>23 <lb/>38 <lb/>20 <lb/>14 <lb/>9 <lb/>4 <lb/>5 <lb/>4 <lb/>7 <lb/>5 <lb/>6 10 <lb/>5 <lb/>6 <lb/>3 <lb/>7 <lb/>9 <lb/>9 <lb/>6 <lb/>4 <lb/>3 <lb/>6 <lb/>7 <lb/>5 <lb/>4 <lb/>3 <lb/>5 <lb/>6 <lb/>7 <lb/>6 10 11 <lb/>0 <lb/>10 <lb/>20 <lb/>30 <lb/>40 <lb/>50 <lb/>60 <lb/>70 <lb/>80 <lb/>90 <lb/>100 <lb/>% <lb/>Inpatient care* <lb/>Outpatient care** <lb/>Long-term care <lb/>Medical goods <lb/>Collective services <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>12 <lb/></page>

			<body>Figure 3: Average annual growth rates of health spending for selected functions, in real terms, OECD average, <lb/>2008 to 2011 <lb/>Source: OECD Health Statistics 2013 <lb/>Hospital funding in OECD countries <lb/>16. <lb/>The source of funding for hospitals differs between OECD countries and is intrinsically linked to <lb/>the structure of the health system. How a patient is protected against the cost of hospital care defines the <lb/>main financing block of a country&apos;s health system. The characteristics of basic health care coverage in <lb/>OECD countries are presented below, followed by an outline of the various hospital payment methods <lb/>used. <lb/>Hospital costs are mainly financed by the public sector <lb/>17. <lb/>In OECD countries, there are two major sources of funding, depending on the characteristics of <lb/>each country&apos;s system for covering health care costs (Table 1). National health systems of the kind seen in <lb/>the United Kingdom, Portugal and Spain, and local health systems such as those in Finland and Sweden, <lb/>are funded mainly through taxation. Health insurance systems, on the other hand, are predominantly <lb/>funded out of employees&apos; and employers&apos; social insurance contributions and can be implemented by one or <lb/>multiple insurance funds. Most countries with multiple health insurers have a range of competing insurers, <lb/>that is, an individual can choose between different insurance funds (e.g. Czech Republic, Germany, Israel). <lb/>However, in some other countries with multiple insurers, such as France, Belgium, Austria and Japan, <lb/>affiliation to one insurance fund is automatic, depending, for example, on an individual&apos;s occupation. <lb/>4.8% <lb/>4.8% <lb/>5.9% <lb/>2.9% <lb/>6.9% <lb/>2.5% <lb/>3.2% <lb/>4.6% <lb/>6.2% <lb/>2.8% <lb/>6.4% <lb/>3.5% <lb/>0.7% <lb/>0.9% <lb/>5.3% <lb/>0.2% <lb/>-1.5% <lb/>-0.9% <lb/>1.0% <lb/>1.7% <lb/>1.6% <lb/>-1.7% <lb/>-1.7% <lb/>1.7% <lb/>-3% <lb/>-2% <lb/>-1% <lb/>0% <lb/>1% <lb/>2% <lb/>3% <lb/>4% <lb/>5% <lb/>6% <lb/>7% <lb/>8% <lb/>Inpatient care Outpatient care Long-term care Pharmaceuticals <lb/>Prevention <lb/>Administration <lb/>2007/08 <lb/>2008/09 <lb/>2009/10 <lb/>2010/11 <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>13 <lb/></page>

			<body>Table 1: Basic health care coverage in the OECD countries <lb/>Main source of basic health care cover <lb/>Countries <lb/>Tax-funded system of health care <lb/>Australia, Canada, Denmark, Finland, Hungary, <lb/>Iceland, Ireland, Italy, New Zealand, Norway, Portugal, <lb/>Spain, Sweden, United Kingdom <lb/>Health insurance <lb/>system <lb/>Single payer <lb/>Korea, Luxembourg, Poland, Slovenia, Turkey, <lb/>Greece* <lb/>Multiple insurers with <lb/>automatic affiliation <lb/>Austria, Belgium, France, Japan, Mexico <lb/>Multiple insurers with free <lb/>choice of insurer <lb/>Chile, Czech Republic, Germany, Israel, Netherlands, <lb/>Slovakia, Switzerland, USA <lb/>* As of 2012 <lb/>Source: OECD Health System Characteristics Survey 2012 <lb/>18. <lb/>Although tax-funded and health insurance systems have differences in terms of access and <lb/>entitlement to health care goods and services, they share similarities in the way hospital costs are financed. <lb/>On average, across OECD countries, 88% of hospital costs were funded by the public sector in 2011. The <lb/>exception is the United States where private insurers meet 36% of hospital costs. This is due to the fact in <lb/>the US private insurers provide basic cover to 53% of the population. In most other OECD countries, <lb/>private insurance has a much more limited role, providing either complementary (e.g. France, Belgium, <lb/>Slovenia, Luxembourg) or supplementary coverage (e.g. Netherlands, Israel, Canada, Austria, Switzerland, <lb/>Finland) to their populations. As a result, private insurers finance only around 5% of hospital spending, on <lb/>average. Some hospital costs are also financed directly from patients: 6% on average across the OECD <lb/>compared to 20% of total spending on health (OECD, 2013). This shows that public coverage for hospitals <lb/>costs in OECD countries is generally higher than for other health care goods or services <lb/>(e.g. pharmaceuticals). <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>14 <lb/></page>

			<body>Figure 4: Structure of hospital cost funding in 2011 (or nearest year) <lb/>Source: OECD Health Statistics 2013 <lb/>19. <lb/>The financing structure of hospitals not only varies between countries but can also differ between <lb/>public and private hospitals within a country (Figure 5). This suggests that the nature of health care <lb/>provided by public and private hospitals may sometimes differ. In France, the funding of public and private <lb/>hospitals is similarly structured (90% covered by the public sector), which means that private hospitals are <lb/>reimbursed by health insurance funds for the care they deliver on the same basis as public hospitals. The <lb/>same holds for Finland. By contrast, in Spain, Portugal and Greece, the funding structures are quite <lb/>different, suggesting that treatments performed by private hospitals are not entirely covered by basic health <lb/>insurance. In Spain, for example, the public sector meets 100% of the costs of care provided in public <lb/>hospitals but only 66% of the costs of private hospital care. <lb/>0% <lb/>10% <lb/>20% <lb/>30% <lb/>40% <lb/>50% <lb/>60% <lb/>70% <lb/>80% <lb/>90% <lb/>100% <lb/>Gen Govt <lb/>Social Security <lb/>Private Health Insurance <lb/>Private OOP <lb/>Rest <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>15 <lb/></page>

			<body>Figure 5: Structure of public and private hospital funding in 2011 (or nearest year) <lb/>Note: No data for the other OECD countries. <lb/>Source: OECD Health Statistics 2013. <lb/>Trend towards DRG-based payment in health insurance systems <lb/>20. <lb/>In 2012, the OECD conducted a survey of the institutional characteristics of its member <lb/>countries&apos; health systems 3 . This survey describes country-specific arrangements for covering the <lb/>population against health risks and financing health spending. It depicts the organisation of health care <lb/>delivery, focusing on the public/private mix of health care provision, provider payment schemes, user <lb/>choice and competition among providers, as well as the regulation of health care supply and prices. Finally, <lb/>it provides information on governance and resource allocation in health systems (decentralisation in <lb/>decision-making, nature of budget constraints and priority setting). Part of this survey was dedicated to the <lb/>modes of payment and the organisation of inpatient care. <lb/></body>

			<note place="footnote">3 <lb/>The complete survey and selected results can be found here: http://www.oecd.org/els/health-<lb/>systems/characteristics.htm <lb/></note>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>16 <lb/></page>

			<body>Box 1. Definition of main hospital payment systems <lb/>Global budget <lb/>Total amount allocated prospectively to the hospital to fund its activities over the course of the year. <lb/>Generally, hospitals have some degree of autonomy in deciding how funds are used. <lb/>Line-item budgeting <lb/>Line-item budgeting follows the same principle as the global budget except that funds are allocated to <lb/>different cost items or services. The main difference between these two budgeting mechanisms is the hospital&apos;s <lb/>degree of freedom in allocating resources among its various activities. <lb/>DRG-based payment <lb/>In general, DRG-based payment (or payment per case) funds all the services and deliverables required <lb/>during a hospital stay in one single payment, with some exceptions for possible additional payments such as <lb/>expensive medication. In this payment system, patients are clustered into groups according to their diagnosis and <lb/>the procedures performed. The aim is to create patient groups that use a similar amount of resources in the <lb/>course of the treatment and thus reflect a similar cost for service provision. Hospitals receive an identical <lb/>payment (DRG tariff) for each patient within a DRG category, with possible adjustments (e.g. by regions, for <lb/>outliers, etc.). DRG tariffs are usually set on the basis of the national average costs of all the services included in <lb/>a DRG, calculated from a sample of hospitals. The payment a hospital receives is known prospectively and <lb/>irrespective of the length of stay and the actual costs incurred. In practice, DRG rates can be either defined as <lb/>relative weights, to be multiplied by a &quot; nominal point value &quot; to obtain a monetary value, or as a &quot; raw tariffs (see <lb/>table below). Adjustments can be applied to DRG tariffs to allow, for example, for specific factors such as hospital <lb/>location, hospital status or patient characteristics. <lb/>Table: DRG weight approach <lb/>Source: adapted from Busse (2011) <lb/>Fee-for-service payment <lb/>In a fee-for-service payment scheme, hospitals are remunerated retrospectively for every service and <lb/>procedure performed in the course of the treatment of a patient. <lb/>Per-diem payment <lb/>In a per-diem payment regime hospitals are reimbursed retrospectively on the basis of the number of days <lb/>spent in hospital. They receive a fixed amount for each patient day. The daily rates may differ between different <lb/>specialties but also between different types of care (e.g. intensive care). <lb/>21. <lb/>Countries with health insurance systems tend to use DRG-based payment systems as the main <lb/>method to finance hospital inpatient activity (Table 2) <lb/>4 : 70% of them have opted for DRG-based payments <lb/>to public hospitals (14 out of 20) while the remaining countries rather use prospective global budget <lb/>(Belgium, Luxembourg) or fee-for-service payment (Israel, Korea, Slovakia). <lb/>4 <lb/>Countries were identified to identify the main method used by the key purchasers to pay for acute care. <lb/>Additional methods exist in a number of countries which are not shown in the table. <lb/>DRG weight <lb/>Monetary <lb/>conversion* <lb/>Adjustment <lb/>Hospital payment <lb/>tariff <lb/>Relative weights <lb/>1.95 <lb/>EUR 2000 <lb/>EUR 3900 <lb/>Raw tariff <lb/>EUR 3000 <lb/>1.3 <lb/>EUR 3900 <lb/>* may be set for each individual hospital <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>17 <lb/></page>

			<body>22. <lb/>Most countries with health insurance systems (14 out of 20 countries) have the same main <lb/>method of hospital payment regardless of a hospital&apos;s legal status (Table 2). Nine of these use DRG-based <lb/>payment systems (Austria, France, Germany, Japan, Netherlands, Poland, Slovenia, Switzerland) while <lb/>five exclusively use either global budgets or fee-for service payments. There are advantages of applying a <lb/>single payment system as they tend to allow for more efficient management of the system and achieve <lb/>economies of scale for the development of information technology. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>18 <lb/></page>

			<body>Table 2: Main hospital payment method used by health insurance systems, by legal status of hospitals, in <lb/>2012 <lb/>Public hospital <lb/>Private not-for-profit <lb/>hospital <lb/>Private for-profit <lb/>hospital <lb/>Austria <lb/>DRG-based <lb/>DRG-based <lb/>DRG-based <lb/>Belgium <lb/>Global budget <lb/>Global budget <lb/>n.a. <lb/>Chile <lb/>DRG-based <lb/>DRG-based <lb/>Line-item remuneration <lb/>Czech Republic <lb/>DRG-based <lb/>DRG-based <lb/>DRG-based <lb/>Estonia <lb/>DRG-based <lb/>France <lb/>DRG-based <lb/>DRG-based <lb/>DRG-based <lb/>Germany <lb/>DRG-based <lb/>DRG-based <lb/>DRG-based <lb/>Greece <lb/>DRG-based <lb/>DRG-based <lb/>Fee-for-service <lb/>Hungary <lb/>DRG-based <lb/>DRG-based <lb/>Fee-for-service <lb/>Israel <lb/>Fee-for-service <lb/>Fee-for-service <lb/>Fee-for-service <lb/>Japan <lb/>DRG-based <lb/>DRG-based <lb/>n.a. <lb/>Korea <lb/>Fee-for-service <lb/>Fee-for-service <lb/>n.a. <lb/>Luxembourg <lb/>Global budget <lb/>Global budget <lb/>n.a. <lb/>Mexico <lb/>Global budget <lb/>Fee-for-service <lb/>Fee-for-service <lb/>Netherlands <lb/>DRG-based <lb/>DRG-based <lb/>n.a. <lb/>Poland <lb/>DRG-based <lb/>DRG-based <lb/>DRG-based <lb/>Slovakia <lb/>Fee-for-service <lb/>Fee-for-service <lb/>Fee-for-service <lb/>Slovenia <lb/>DRG-based <lb/>DRG-based <lb/>DRG-based <lb/>Switzerland <lb/>DRG-based <lb/>DRG-based <lb/>DRG-based <lb/>USA (Medicare) <lb/>DRG-based <lb/>DRG-based <lb/>Fee-for-service <lb/></body>

			<note place="footnote">Source: OECD Health System Characteristics Survey 2012. <lb/></note>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>19 <lb/></page>

			<body>23. <lb/>Tax-funded national health systems tend to pay hospitals using a prospective global budget <lb/>(Table 3). Two-third of them (9 out of 13) use global budget the main payment method to finance public <lb/>hospitals and only three of those countries (Australia, Finland and the United Kingdom) use a DRG-based <lb/>system. Some countries such as Sweden, Norway and Portugal use a DRG-based classification for <lb/>managing hospital budgets but pay their hospitals out of a global budget. Fee-for-service payment and line-<lb/>item remuneration are also less commonly used in tax-funded systems. <lb/>24. <lb/>Countries with tax-funded systems generally pay hospitals differently according to their status, <lb/>with the exception of Canada, Ireland and Sweden. One possible explanation for the greater diversity in <lb/>hospital payment methods in tax-funded health systems may stem from the tendency of national health <lb/>systems in a number of countries to limit coverage to public providers. Hence, in a parallel private sector <lb/>where services need to be financed either out-of-pocket or via private insurance a different remuneration <lb/>system for hospital activity might have developed. <lb/>Table 3: Main method used to pay hospitals, by legal status, in 2012 in systems funded by taxation <lb/>Public hospital <lb/>Private not-for-profit <lb/>hospital <lb/>Private for-profit <lb/>hospital <lb/>Australia <lb/>DRG-based <lb/>Fee-for-service <lb/>Fee-for-service <lb/>Canada <lb/>Global budget <lb/>Global budget <lb/>Global budget <lb/>Denmark <lb/>Global budget <lb/>n.a. <lb/>DRG-based <lb/>Finland <lb/>DRG-based <lb/>Iceland <lb/>Global budget <lb/>n.a. <lb/>n.a. <lb/>Ireland <lb/>Global budget <lb/>Global budget <lb/>Italy <lb/>Global budget <lb/>DRG-based <lb/>DRG-based <lb/>New Zealand <lb/>Global budget <lb/>n.a. <lb/>n.a. <lb/>Norway <lb/>Global budget <lb/>Global budget <lb/>DRG <lb/>Portugal <lb/>Global budget <lb/>Fee-for-service <lb/>Fee-for-service <lb/>Spain <lb/>Line item remuneration <lb/>Global budget <lb/>Sweden <lb/>Global budget <lb/>Global budget <lb/>Global budget <lb/>United Kingdom <lb/>DRG-based <lb/>Fee-for-service <lb/>Fee-for-service <lb/></body>

			<note place="footnote">Source: OECD Health System Characteristics Survey 2012. <lb/></note>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>20 <lb/></page>

			<body>25. <lb/>The increasing use of DRG-based payments serves as a financial incentive to hospitals to reduce <lb/>costs per patient and average length of stay thus improving technical efficiency. But payment via DRG also <lb/>encourages hospitals to treat more patients, increasing hospital activity when marginal revenue is above the <lb/>marginal cost per patient. In an attempt to limit spending growth which may be a consequence of the <lb/>introduction of DRG payment schemes, some OECD countries have reduced the DRG tariffs above a pre-<lb/>defined volume of production, using a mechanism known as tapering payment. As a result, hospitals are <lb/>paid less for a case once a certain level of hospital activity has been reached. The main reason given to <lb/>justify these reductions is that economies of scale can be achieved within the hospital production system. <lb/>Above a pre-defined level of hospital activity, the hospital is deemed to have covered all fixed costs and <lb/>consequently should be paid only for its variable costs. An analysis of the economic literature will <lb/>illuminate this debate on economies of scale within the hospital sector and enable us to judge the merits of <lb/>this reduction in tariffs above a defined threshold of activity. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>21 <lb/></page>

			<body>ECONOMIES OF SCALE IN HOSPITALS: A LITERATURE REVIEW <lb/>26. <lb/>Economies of scale can be observed in the production process in many industries. It refers to the <lb/>situation where average unit costs decrease with an increase in output. The extent to which economies of <lb/>scale can be generated depends on the cost structure of the industry. In industries that produce goods or <lb/>services involving huge capital investments, the fixed costs per unit of production is high and an additional <lb/>unit is relatively cheaper to produce, since only variable costs need to be taken into account. Consequently, <lb/>the average cost of production per unit falls with each additional unit produced within certain limitations. <lb/>27. <lb/>Two approaches have been followed when analysing the existence of economies of scale in the <lb/>hospital sector: an accounting and an economic approach. The accounting approach consists in analysing <lb/>the cost structure of the production of services. However, this static approach must be complemented by a <lb/>dynamic analysis to take account of the existence of semi-variable costs, those costs which increase in <lb/>steps. The economic approach is based on a literature review of published studies that analyse the <lb/>existence of economies of scale in hospitals. <lb/>28. <lb/>While the accounting approach and most of the published literature suggest that there are <lb/>economies of scale in the hospital sector, there are also articles, in some cases of questionable <lb/>methodology, that have highlighted diseconomies of scale in hospitals. <lb/>Accounting approach: identification of the proportion of fixed costs in hospital care production <lb/>Static approach: for some procedures, fixed costs represent the majority of production costs <lb/>29. <lb/>Busse et al. (2008) analysed the cost structure of ten different types of treatment across nine <lb/>European countries. Five of these procedures are performed as inpatient care in hospitals, namely <lb/>appendectomy, normal childbirth, hip replacement, the treatment of stroke and of acute myocardial <lb/>infarction (Table 4). <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>22 <lb/></page>

			<body>Table 4: The different procedures analysed in the Health Benefit Basket project <lb/>Treatment <lb/>Patient characteristics <lb/>Location where carried <lb/>out <lb/>Case type 1 <lb/>Appendectomy <lb/>Male, 14 to 25 years <lb/>Inpatient care <lb/>Case type 2 <lb/>Normal childbirth <lb/>Female, 25 to 34 years <lb/>Inpatient care <lb/>Case type 3 <lb/>Hip replacement <lb/>Female, 65 to 75 years <lb/>Inpatient care <lb/>Case type 4 <lb/>Stroke <lb/>Male, 60 to 70 years <lb/>Inpatient care <lb/>Case type 5 <lb/>Acute myocardial <lb/>infarction <lb/>Male, 50 to 60 years <lb/>Inpatient care <lb/>Source: Busse et al. (2007). <lb/>30. <lb/>To collect pertinent data, a sample of at least five representative health care providers were <lb/>identified in the participating countries for the different case types of selected procedures (that is, at least <lb/>five hospitals for inpatient care). For the inpatient procedures, data from &quot; acute care general hospitals &quot; <lb/>with 200 to 400 beds was analysed, assuming this reflects the way the service is currently organised. <lb/>However, this method of selecting hospitals does not guarantee that the results given below are <lb/>representative across the board. The methodology used ensures that the costs in the selected hospitals are <lb/>measured consistently and that the results are comparable to a certain extent across different countries; but <lb/>a study based on a larger sample within a single country could give different results. <lb/>31. <lb/>The costs of the different procedures were divided into five items: cost of diagnosis, cost of <lb/>hospital staff (nurses, doctors), costs associated with the surgical procedure (surgeon, anaesthetist, etc.), <lb/>and costs of pharmaceuticals and, finally, general expenses. The vast majority of general expenses are <lb/>made up of fixed costs for care production <lb/>5 . These are the costs associated with medical and non-medical <lb/>infrastructure (administration, water, electricity, laundry services, buildings maintenance, etc.) and <lb/>depreciation costs. <lb/>32. <lb/>The proportion accounted for by general expenses in the total cost of the selected procedures (hip <lb/>replacement, acute myocardial infarction, appendectomy and normal childbirth) varies from 23% in France <lb/>in the case of infarction to 64% in the case of childbirth. The proportion of general expenses in France is <lb/>close to the average of the other countries, for hip replacement and myocardial infarction. For <lb/>appendectomy and childbirth, general expenses in France are 10 and 17 percentage points respectively <lb/>higher than the average of the nine countries analysed in the study. <lb/>5 <lb/>General expenses include non-medical infrastructure such as administrative staff, cleaning, gardening, <lb/>technical staff, buildings maintenance, power, water, tax and insurance (where this is part of patient <lb/>services), rent, depreciation costs for equipment and buildings, and financing costs. They also cover certain <lb/>medical infrastructure expenses such as laundry, sterilisation, patient transport (to hospital), catering and <lb/>the time spent on administration by the medical and nursing staff. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>23 <lb/></page>

			<body>Figure 6: Proportion accounted for by general expenses in four inpatient procedures in France and averaged <lb/>over nine OECD member countries <lb/>Source: Busse et al. (2007). <lb/>33. <lb/>The fact that general expenses are such a large proportion of the total cost of hospital care <lb/>supports the hypothesis that economies of scale are possible in the hospital sector. For DRG-based <lb/>payment systems, a calculation of the average production cost over a sample of different hospitals is often <lb/>used when setting DRG tariffs. Thus, the high proportion of general expenses in the production cost of care <lb/>could justify a tapering scale for the fees associated with each treatment, once general expenses have been <lb/>covered. However, this static accounting approach is challenged when the hospital production system is <lb/>analysed dynamically. <lb/>Dynamic approach: semi-variable expenses must be taken into account when calculating the cost <lb/>structure of hospitals <lb/>34. <lb/>While a static approach to hospital production costs allows for a distinction to be made between <lb/>fixed and variable costs, the dynamic accounting model takes into account a third type: semi-variable costs. <lb/>The amount spent on semi-variable expenses varies with the amount of activity, though it is not <lb/>proportional to it. Thus, as production grows, the associated costs of these expenses may, for example, <lb/>increase in steps. This in turn entails marginal costs which change in steps. <lb/>35. <lb/>The existence of semi-variable costs for hospital care is, partially, attributable to regulations <lb/>which stipulate that hospital capacity will rise as a function of the volume of production of care. As a result <lb/>of these regulations, the fact that variable and semi-variable charges increase as activity increases may <lb/>question the theory of a decreasing average cost of production. As production increases, the hospital may <lb/>indeed initially see its average cost of production fall; but beyond a certain production level the hospital <lb/>must reinvest in new equipment or take on new staff, which has the effect of a jump in production costs. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>24 <lb/></page>

			<body>Consequently, marginal-cost pricing above a certain level of activity should be adapted to take into account <lb/>these steps in the level of semi-variable costs. <lb/>36. <lb/>While the accounting approach sheds light on the existence of economies of scale by identifying <lb/>fixed and variable costs in the care production system, an analysis of the economic approach with reference <lb/>to a review of the literature that analyses the production function in hospitals complements this analysis. <lb/>Literature review of the economic studies relating to the existence of economies of scale in hospitals <lb/>37. <lb/>The empirical literature has considered economies of scale in hospitals from two different angles. <lb/>Much of the literature has analysed the relationship between the size of hospitals and the cost of care <lb/>provided, trying to identify the optimum size of hospitals. A second approach, covered by much less <lb/>literature, has attempted to establish the relationship between the level of activity of hospitals and the cost <lb/>of care production. Here, the underlying question is how production costs change when the quantity of care <lb/>provided increases. Literature covering the second approach is relevant to explore marginal costs for care <lb/>beyond a certain level of activity. <lb/>38. <lb/>A literature review identified nine published studies assessing the relationship between the cost <lb/>of production and the quantity produced within the hospital sector. The majority of these studies focus on <lb/>the Unites States. In these studies, elasticities in the cost of production with respect to the quantity <lb/>produced have been calculated which served as a tool to measure the extent of economies of scale. <lb/>Theoretical model and econometric models <lb/>39. <lb/>A theoretical analysis of the firm production function requires the adoption of an explicit <lb/>hypothesis of the state of equilibrium within the enterprises of each sample analysed. If the enterprises are <lb/>considered to be on a long-term path, that is to say if the level of utilisation of inputs minimises costs, <lb/>taking into account the level of production and the cost of production factors, then we may base the <lb/>evaluation on a long-term cost function, in which total costs are expressed as a function of the quantities of <lb/>different outputs and the cost of inputs. On the other hand, the enterprises may not be in a position to <lb/>change the production factors as a whole quickly in response to changes in the production level or the cost <lb/>of production factors. Where this is the case, enterprises in this sector will, in the short term, aim to utilise <lb/>optimum quantities of the variable inputs which can easily be adjusted (such as workforce and equipment), <lb/>taking into account the levels of fixed inputs, even if these are not optimal (such as capital costs). In this <lb/>case, evaluation is based on a short-term production function. The variable cost function is then defined <lb/>using as parameters the level of outputs, the cost of inputs and the overall figure for fixed costs (Vita, <lb/>1990). <lb/>40. <lb/>Most of the studies (six out of nine) assess a short-term production function for hospitals, taking <lb/>the capital costs as fixed in their analysis. In order to evaluate the cost functions, the studies take two <lb/>principal production functions which are flexible and linear, and which do not require hypotheses to be <lb/>applied to the production structure, as is for example the case with Cobb-Douglas production functions or <lb/>CES (constant elasticity of substitution). In this way, the studies apply the generalised Leontief production <lb/>function and the translog production function <lb/>6 . <lb/></body>

			<note place="footnote">6 <lb/>For instance, the following specification is used with a translog cost function: ln(C) = <lb/>α+∑β i Y i +µ∑θ ij Y i Y j +∑δ i Y i <lb/>3 +ηln(P)+∑λ i PY i +∑μ k Z k +ε where C is total or variable cost, Y is a vector of <lb/>outputs, P represents input prices, Z is a vector of other factors that shift the cost function and ε is a <lb/>residual error term (Menke, 1997). <lb/></note>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>25 <lb/></page>

			<body>41. <lb/>The variable discussed (dependent variable) in the econometric analyses is primarily the total <lb/>variable cost, which groups together the cost of labour and the cost of pharmaceuticals and medical <lb/>equipment&apos;s use. In this case, the total operating costs represent the variable cost to be identified (Li et al., <lb/>2001). <lb/>42. <lb/>For the explanatory variables, in most of the studies, the outputs used to characterise the <lb/>production function are the number of patient-days in hospital per annum. Vita (1990) considers separately <lb/>two variables: the number of discharges or admissions and the average length of stay in hospital. These <lb/>two variables allow a consideration of the two ways by which a hospital may increase the number of days <lb/>of care provided. In parallel, so that the impact of the different outputs on production costs may be <lb/>measured with precision, some studies make a distinction between the different services within hospital <lb/>production. Thus, for example in the study by Cowing and Holtmann (1983), hospital production is divided <lb/>into five diagnostic categories: medical-surgical, maternity, paediatrics, emergency room and other. <lb/>43. <lb/>The price of inputs corresponds to salaries but also when they are available the prices of <lb/>medicines and medical devices. Most of the studies (six out of nine) categorise the salaries by <lb/>qualification. For example, Cohen et al. (2008) make a distinction between the salaries of medical staff for <lb/>seven different expense items within the scope of care production, such as surgery, radiology and the <lb/>salaries of administrative staff. However, some studies do not have sufficient data to calculate salary levels <lb/>by hospital and by service. In this case, some studies use of a global salary index for the region in which <lb/>the hospital operates (Carey, 2000, and Menke, 1997). <lb/>44. <lb/>So that the heterogeneous nature of hospitals can be taken into account, additional explanatory <lb/>variables are applied to all the econometric analyses. First, the legal status of the hospital allows for <lb/>differences in cost between public, private for-profit and private not-for-profit hospitals to be taken into <lb/>account. Inclusion of this variable in particular can potentially verify the hypothesis that private for-profit <lb/>hospitals will bring about greater efficiency of production and hence lower costs (Carey, 2000). Second, <lb/>the hospital case mix enables to account for differences in the severity of cases treated by hospitals which <lb/>could have an impact in particular on the equipment at the hospital but also on the qualifications of medical <lb/>staff (Li et al., 2001). Finally, other variables which may have an impact on production costs are included, <lb/>such as the geographical location of the hospital, the university hospital status or the Herfindahl index, in <lb/>order to measure the level of competition faced by the hospital. <lb/>Data used in studies <lb/>45. <lb/>Most of the studies use administrative data to evaluate the cost functions of the hospitals. Five <lb/>out of nine studies use data from the different US States departments of health. For example, Li et al. <lb/>(2001) utilise the annual data submitted by hospitals to the Washington State Department of Health. This <lb/>data includes details on the financial situation of each hospital and its activity. The other three American <lb/>studies take survey data either for a particular state (State of California in the case of Vita, 1990) or the <lb/>whole of the United States (Carey, 2000, and Menke, 1997). The latter two studies refer to the annual <lb/>survey by the American Hospital Association as a basic data source, which is supplemented with additional <lb/>data. For example, Menke (1997) adds to this survey data from the Bureau of the Census to obtain salaries <lb/>broken down by region. <lb/>46. <lb/>The data used suffers from certain limitations, which mean that caution is necessary when <lb/>generalising from the results presented. Most of the studies use panel data for periods of between four to <lb/>seven years. In particular, panel data allows the heterogeneous nature of hospitals to be taken properly into <lb/>account and thus to obtain more robust evaluations. However, three of the studies refer only to a single <lb/>year (Cowing et al., 1983, Vita, 1990, and Menke, 1997), which means that instead of observing the <lb/>evolution of costs of each hospital when its activity increases, they observe differences in costs between <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>26 <lb/></page>

			<body>hospitals with different levels of activity. It is thus possible that a bias exists, if the hospitals with greater <lb/>activity are hospitals that are systematically more (or less) efficient. Moreover, six out of the nine studies <lb/>use data relating to periods before 1990. Finally, three studies relate to a very small number of institutions. <lb/>Cohen et al. (2010) refer to 30 hospitals in the State of Connecticut, and Cohen et al. (2011) refer to <lb/>17 hospitals in Washington State. Small sample sizes may question the robustness of the results and <lb/>caution is needed when drawing any general conclusions from the results. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>27 <lb/></page>

			<body>Table 5: Description of data used when evaluating economies of scale in the hospital sector and cost elasticity <lb/>Date <lb/>Authors <lb/>Country <lb/>Data <lb/>Types of data <lb/>Number of hospitals <lb/>Cost <lb/>elasticity <lb/>1983 <lb/>Cowing <lb/>et al. <lb/>USA <lb/>Administrative data from New York State <lb/>Cross-sectional data <lb/>1975 <lb/>138 general hospitals <lb/>0.86 <lb/>1990 <lb/>Vita <lb/>USA <lb/>California Health Facilities Survey (1983) <lb/>Cross-sectional data <lb/>1983 <lb/>296 general hospitals <lb/>1.26 <lb/>1997 <lb/>Menke <lb/>USA <lb/>Annual survey of American Hospital Association <lb/>Bureau of the Census (salary data) <lb/>Guide to Hospital Performance (HCIA) for quality indicators <lb/>The Area Resource File (ARF) for information on the region <lb/>in which hospital is established <lb/>Cross-sectional data <lb/>1990 <lb/>2 200 hospitals <lb/>Not <lb/>quantified <lb/>2006 <lb/>Smet <lb/>Belgium <lb/>Administrative data from the Belgian Federal Public Service <lb/>of Health, Food Chain Safety and Environment <lb/>Cross-sectional data <lb/>1997 <lb/>187 general hospitals <lb/>1.15 <lb/>2000 <lb/>Carey <lb/>USA <lb/>Annual survey of American Hospital Association <lb/>Data from Healthcare Financing Administration, based on <lb/>Hospital Cost Reporting Information System <lb/>Panel data <lb/>1987-1991 <lb/>1 733 hospitals <lb/>0.68 <lb/>2001 <lb/>Li et al. <lb/>USA <lb/>Administrative data from Washington State (Health <lb/>Department) <lb/>Panel data <lb/>1988 to 1993 <lb/>910 hospitals <lb/>0.62 <lb/>2008 <lb/>Cohen <lb/>et al. <lb/>USA <lb/>Administrative data from Washington State (Health <lb/>Department) <lb/>Panel data <lb/>1997 to 2002 <lb/>93 hospitals <lb/>0.68 <lb/>2010 <lb/>Cohen <lb/>et al. <lb/>USA <lb/>Administrative data from the State of Connecticut <lb/>(Department of Public Health) <lb/>Panel data <lb/>2006 to 2008 <lb/>30 hospitals <lb/>2.27 <lb/>2011 <lb/>Cohen and <lb/>Paul <lb/>USA <lb/>Administrative data from Washington State (Health <lb/>Department) <lb/>Panel data <lb/>1997 to 2004 <lb/>17 hospitals <lb/>0.75 <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>28 <lb/></page>

			<body>Results <lb/>47. <lb/>Most of the studies find that there are economies of scale in the hospital sector. More precisely, <lb/>five out of the nine studies analysing economies of scale conclude that, if a hospital increases its activity, <lb/>the total costs associated increases less than proportionally to the increase in activity. The elasticity varies <lb/>between 0.62 (Li et al., 2001) and 0.86 (Cowing et al., 1987), which means that a 1% increase in activity <lb/>induces an increase in costs by 0.62% to 0.86%, all other things being equal. <lb/>48. <lb/>Three studies conclude that there are diseconomies of scale: Vita (1990), Smet (2006) and Cohen <lb/>et al. (2010). In these studies, the measured elasticity is on average 1.56, which means that an increase in <lb/>hospital activity by 1% brings about an increase of 1.56% of costs in the hospitals studied. These studies, <lb/>in particular those of Smet (2007) and Cohen et al (2011), suffer from some limitations. First, in the study <lb/>by Smet (2007), data relating to input costs and in particular salaries are not available. Thus, the author <lb/>does not include in his analysis the differences in salaries between hospitals or their impact on costs. This <lb/>limitation may create a bias in the results. It may, in fact, be assumed that there is a correlation, expected to <lb/>be positive, between salaries and quantity produced (i.e. a link between better salaries and higher <lb/>productivity). If this is true, the study overestimated the impact of activity on costs. The main limitation of <lb/>the study by Cohen et al. (2010) is the small number of hospitals 30 hospitals), which affects the precision <lb/>of estimates and generalizability of results. <lb/>Box 2. Efficiency in the hospital sector, economies of scope and influence of hospitals&apos; status on costs <lb/>The studies presented for the analysis of economies of scale also shed some light on two important <lb/>problematic areas related to the efficiency of production in the hospital sector. <lb/>First, studies analysing economies of scale also present results on economies of scope in the hospital <lb/>sector. An enterprise can generate economies of scope if it reduces its production costs by widening its range of <lb/>products and services (joint production). Diversification of production may take two different forms: related <lb/>diversification and conglomerate diversification. Related diversification refers to the development of new activities <lb/>that share some characteristics with existing activities. The diversification may be vertical or horizontal. <lb/>Conglomerate diversification refers to the development of new activities which have no common ground with <lb/>existing activities. Only economies of scope from related diversification seem to be appropriate in the hospital <lb/>sector. <lb/>From the studies that were analysed to explore the existence of economies of scale, and some additional <lb/>grey literature we have identified eight studies that deal with economies of scope within the hospital sector. Most <lb/>of these studies analyse economies of scope between inpatient and outpatient care [Menke (1997), Wang et al. <lb/>(2006), Kristensen et al. (2012), Marini et al. (2009), Cohen et al. (2008)]. Only three studies identify economies <lb/>of scope within a hospital. Cowing and Holtmann (1983) demonstrate the existence of economies of scope <lb/>between paediatric services and other services, and diseconomies of scope between emergency room services <lb/>and other services. Kittelsen et al. (2009) identify important economies of scope between surgical and medical <lb/>services but no significant relationship between scheduled care and emergency care. Smet (2007), albeit with the <lb/>limitations suffered by this study, highlights economies of scope between internal medicine and surgical care, and <lb/>surgical care and specialised treatments. <lb/>The second point illuminated by these various studies on hospital costs relates to the efficiency of public, <lb/>private not-for-profit and private for-profit hospitals. The conclusions of the different studies presented here are <lb/>ambiguous. Private for-profit hospitals have lower costs than not-for-profit hospitals, with a difference of around <lb/>15% according to Cowing and Holtmann (1983) and around 5% according to Vita (1990). Carey (2000) finds no <lb/>difference in cost as a function of the legal status of the hospital. Finally, Menke (1997) shows that, among <lb/>independent hospitals, private for-profit and not-for-profit hospitals have higher costs, by 28.7% and 10.7% <lb/>respectively, than public hospitals. Menke (1997) does not find any difference in the costs of private hospitals that <lb/>are part of a group and public hospitals. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>29 <lb/></page>

			<body>49. <lb/>The study by Cohen et al. (2010) suffers from a different bias, caused by a limited quantity of <lb/>data, since the study refers only to 30 hospitals, which has an effect on the precision of the evaluations <lb/>made and on the ability to generalise from the results. <lb/>50. <lb/>In conclusion, there is some empirical evidence of the existence of economies of scale in <lb/>hospitals but it is not unambiguous. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>30 <lb/></page>

			<body>EXPERIENCES OF TAPERING PAYMENT SCALES IN FOUR OECD COUNTRIES <lb/>51. <lb/>Six OECD member countries have introduced tapering payment, based on the assumption that <lb/>economies of scale exist within hospitals. These six countries are Germany, USA (State of Maryland), the <lb/>Czech Republic, Israel, Australia and Hungary. In order to describe the mechanisms in as much detail as <lb/>possible, four case studies have been carried out, based on available data and in-depth discussions with <lb/>experts: Germany, USA (State of Maryland), the Czech Republic and Israel. The aim of these case studies <lb/>is to explain the context of the introduction of this policy, the objectives and the technical details of the <lb/>tapering mechanism, but also to identify the impact of tapering payment on hospital activity. This section <lb/>presents these case studies. For each country, it first provides some contextual background and then <lb/>describes the tapering mechanism and its impact on hospital spending and activity. <lb/>Germany <lb/>Basic facts of health system <lb/>52. <lb/>Germany is a country where social health insurance has traditionally played a huge role in health <lb/>care coverage. In total, around 89% of the population is insured by one of the 134 statutory health <lb/>insurance funds. These are mainly funded through social contributions of employers and employees. The <lb/>remaining 11% are covered by primary private health insurance. Private coverage can be chosen by <lb/>employees earning more than around EUR 4 500 per month, self-employed, and civil servants regardless of <lb/>their income. Unlike protection under the statutory health insurance scheme, private health care coverage is <lb/>subject to individual insurance policies based on risk-related insurance premiums. <lb/>53. <lb/>All statutory health insurance funds basically cover the same basket of health care goods and <lb/>services with a few exceptions. Health care services financed by private insurers can be more generous <lb/>depending on the insurance contract. Some contracts include supplementary insurance components for <lb/>items that are not covered under the public insurance (e.g. access to a single room in a hospital or treatment <lb/>by heads of departments for inpatient care). For outpatient specialist care, some studies showed faster <lb/>access to health professionals for people with private insurance compared to those with public coverage <lb/>(e.g. Roll et al., 2012). <lb/>54. <lb/>A key feature of the German health system is the decisive role of joint self-government of payers <lb/>and providers in the organisation of the system. The main body of the joint self-government is the Federal <lb/>Joint Committee (G-BA) which plays a key role in defining the pharmaceutical products, medical devices <lb/>and diagnostic and therapeutic procedures included under public coverage. The guidelines issued by the G-<lb/>BA are legally binding to insurers and care providers alike, i.e. physicians and hospitals. Moreover, the G-<lb/>BA has important responsibilities for measuring the quality of hospital and outpatient services. Unlike in <lb/>NHS-type systems, the role of the government in the German health system is mainly restricted to defining <lb/>the regulatory framework of health care provision and supervision of the system. <lb/>Hospitals <lb/>55. <lb/>The high number of beds is one of the defining features of the hospital sector in Germany. There <lb/>are 8.3 beds per 1 000 population, ranking Germany third among OECD countries. The average number of <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>31 <lb/></page>

			<body>beds in OECD countries is 4.9 per 1 000 population. There has been a 10% drop in bed capacity between <lb/>2000 and 2011 in Germany compared to an average reduction of 5% in OECD countries. <lb/>56. <lb/>The majority of beds in Germany are provided by private hospitals (either for-profit or non-for-<lb/>profit) at 59%, compared to 27% on average in the OECD. 64% of all hospital beds are allocated to <lb/>curative care, 15% to psychiatric care and 21% to rehabilitative care. <lb/>57. <lb/>The volume of hospital activity in Germany is well above most other OECD countries. The <lb/>number of discharges per 1 000 population in Germany is 55% higher than the OECD average (240 <lb/>compared to 155). However, hospital spending as a share of total health expenditure in Germany is around <lb/>the OECD average (29%). <lb/>58. <lb/>There is a clear separation in the provision of inpatient and outpatient health care in the German <lb/>health system. Apart from a few targeted activities (emergencies and complex treatments for cancer, rare <lb/>diseases, etc.), hospitals are legally not allowed to provide outpatient services. <lb/>Hospital payments in Germany <lb/>Main features of DRG-based payment <lb/>59. <lb/>Around 80% of all hospitals revenues stem from DRG payments (Busse et al., 2011). The DRG <lb/>tariffs received by hospitals are calculated by multiplying relative weights with a base rate. The relative <lb/>weights are set nationwide; the base rates differ at a Länder-level. <lb/>60. <lb/>Payment by DRG was gradually introduced into Germany from 2003 onwards. It applies to <lb/>public and private hospitals alike, whether profit-making or not, using the same DRG catalogue and <lb/>relative weights. There is also no difference in the use of DRGs between patients covered under public or <lb/>private insurance. Remuneration via DRGs applies to medical, surgical and obstetric treatments, including <lb/>day cases. Patients are classified into one DRG on the basis of a patient&apos;s diagnosis, the medical <lb/>procedures provided and patient characteristics (age, gender and new-born weight, length of stay, duration <lb/>of ventilation, reason for hospital discharge and type of admission). A new prospective payment for <lb/>inpatient psychiatric treatment (different per diem rates depending on patient characteristics and <lb/>procedures) is currently under development. Additional payments not incorporated in DRG tariffs are <lb/>made for the use of costly medications or medical devices and innovative treatments. <lb/>61. <lb/>Depreciation is not included in the calculation of DRG-based payments because of the historic <lb/>split in hospital financing in Germany. Current expenses are financed by public and private insurers (now <lb/>mainly via DRG), whereas capital expenses are funded directly by the German Länder. Consequently, the <lb/>calculation of the cost of a treatment group does not take account for capital investment. However, in <lb/>practice, 50% of investments in hospitals are funded from sources other than the Länder (e.g. via credits or <lb/>from hospital&apos;s own income) (See Deutsches Krankenhausinstitut, 2010). <lb/>Relative weights <lb/>62. <lb/>The DRG catalogue comprises 1196 groups in 2014. It is negotiated annually between the federal <lb/>hospital association (DKG) and the federal organisations of health insurance funds (GKV) and private <lb/>health insurance companies (PKV). The German Institute for the Hospital Remuneration System (Institut <lb/>für das Entgeltsystem im Krankenhaus – InEK) calculates the relative weight of each DRG item based on <lb/>cost-intensiveness of the resources used. For this calculation, InEK receives data from 253 hospitals (15% <lb/>of all general hospitals) to help draw up the scale. The weight for the benchmark treatment group is <lb/>1 point. The weights for the other treatment groups are calculated with reference to the benchmark group. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>32 <lb/></page>

			<body>Base rate <lb/>63. <lb/>The relevant base rate for the remuneration of hospitals is negotiated at Länder level, taking into <lb/>account a theoretical-base rate set at the federal level, as a point of reference. <lb/>64. <lb/>At the federal level, the hospital association agrees annually with the organisations of statutory <lb/>health insurers and private insurers on a federal base rate taking into account calculations carried out by <lb/>InEK based on the past base rates in Länder, the effective case mix and total spending, as well as growth in <lb/>total salaries – reflecting the increase of available financial resources of health insurance funds – and an <lb/>index value reflecting changes for costs of staff and equipment in hospitals. The result of these negotiations <lb/>is the monetary value of the federal base rate. <lb/>65. <lb/>In the 16 Länder, regional associations of hospitals and insurers negotiate the regional base rates. <lb/>Factors to be taken into account in these negotiations include the projected development of costs, potential <lb/>efficiency savings, and the prospective change in number and severity of cases (case-mix). Having said <lb/>that, some restrictions in the Länder negotiations apply: Since 2014 Länder base rates must lie within a <lb/>band between +2.5% and -1.25% of the federal base rate 7 . Additionally, the annual increases in the base <lb/>rates at Länder level cannot exceed the increase of the federal base rate. <lb/>66. <lb/>In most of the Länder (9 of the 16), the negotiations in 2014 resulted in a Länder base rate below <lb/>the minimum value of the band. Consequently, these Länder base rates had to be raised to reach this <lb/>threshold. <lb/>Hospital revenue budgets <lb/>67. <lb/>The DRG-payment per case is in general defined by the relative weight of the DRG and the <lb/>Länder base rate but an important element affecting the final payment is related to the individual hospital <lb/>revenue budget. All hospitals need to negotiate case-mix-based target &quot; revenue budgets &quot; with insurers on <lb/>an annual basis. The negotiations involve all insurers that represent at least a 5% share of the hospital&apos;s <lb/>patients; other insurers must accept the results of the negotiation. The main outcome of these negotiations <lb/>is an agreed volume in terms of case-mix for each hospital for the calendar year. In combination with the <lb/>DRG relative weights, this defines the revenue budget. There are two situations related to the revenue <lb/>budgets -explained below -where hospitals do not receive the full DRG tariff for the treatment of the <lb/>patient but only a reduced rate. <lb/>The tapering system <lb/>Technical considerations <lb/>68. <lb/>In Germany two separate mechanisms exist to reduce the hospital tariffs per case within the DRG <lb/>framework. The first type of tapering rate is applied to additional negotiated hospital volumes; the second <lb/>is applied to all volume beyond the negotiated revenue budget, i.e. the non-negotiated volume. <lb/> Any increase in activity volume (based on the case-mix) compared to year t-1 within the range of <lb/>negotiated volumes for year t is reimbursed at rate tapered by 25% (rate in force in 2013 and <lb/>2014) 8 . This mechanism is known as the Mehrleistungsabschlag 9 or MLA. <lb/>7 <lb/>Exceptions apply to those Länder who have been historically above this band; their base rates are only <lb/>gradually reduced to finally reach the upper limit of the corridor. <lb/></body>

			<note place="footnote">8 <lb/>As an exception, tapering rates are applicable in 2014 for all additional volume as compared to t-2. <lb/></note>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>33 <lb/></page>

			<body> Hospitals have to pay back 65% of all revenue related to activity exceeding the negotiated <lb/>volume. This means hospitals can only keep 35% of these additional revenues. This mechanism <lb/>is known as the Mehrerlösausgleich 10 or MEA. As a counterbalance for the tapering rate, all <lb/>negotiated services which could not be delivered are paid by insurers at a rate of 20%. <lb/>69. <lb/>An overview of the technical application of the two rates is displayed in Chart 1. For MLA, the <lb/>tapered rate changed continually between 2009 and 2014. In 2009 -the year of its introduction -the rate <lb/>was negotiated for each Land separately, averaging out at 24%. Tapering was abandoned for negotiated <lb/>volumes in 2010 but reintroduced in 2011 with a tapered rate of 30%. The rate was again negotiated in <lb/>2012, and in 2013 and 2014 it was set at 25%. Moreover, the benchmark year for calculating additional <lb/>volumes in 2013 and 2014 was 2012. <lb/>9 <lb/>Literally &quot; reduction for increased services &quot; . <lb/>10 <lb/>Literally &quot; compensation for surplus &quot; . <lb/>DELSA/HEA/WD/HWP(2015)1 <lb/>34 <lb/>Chart 1: Hospital payments in Germany <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>35 <lb/></page>

			<body>70. <lb/>The first level of tapering (MLA) is applicable to all DRGs with some exceptions. In practical <lb/>terms, the monetary value of the MLA is only known after the negotiation of hospital volumes and the <lb/>MLA translates into a percentage reduction of all DRGs billed to insurers after the negotiated volume is <lb/>agreed on. Some negotiated additional services are exempt from this reduction, for example, in the case of <lb/>transplants, volume growth that is based on increases in hospital capacity, DRGs where material costs <lb/>account for more than two-thirds of the total cost, and in hardship cases. <lb/>71. <lb/>The MEA applies to the non-negotiated volume; 65% of all revenues exceeding the revenue <lb/>budget which is based on the negotiated volume have to be reimbursed by hospitals. But some exceptions <lb/>also apply, for example, for additional revenues generated from treatment of severely injured patients; in <lb/>these cases, a 25% reduction is applied which means that hospitals can keep 75% of the additional <lb/>revenues. <lb/>Rationale for introduction <lb/>72. <lb/>Tapering payment in Germany was introduced in 1985 in Germany, before DRG-based <lb/>payments, when hospitals were still paid through per-diem rates. During that period, payments for <lb/>additional treatments which resulted in revenues in excess of the negotiated budgeted revenue had to be <lb/>partially reimbursed by the hospital. The reduction was justified by economies of scale in hospital <lb/>production. This assumption, however, does not seem to have been based on empirical evidence at that <lb/>time. It was argued that fixed costs of hospitals were already completely covered with payments generated <lb/>within the negotiated hospital budget; payment for additional cases would therefore only have to reflect <lb/>variable costs. By the same reasoning, hospitals received partial payments for the non-generated cases that <lb/>fell short of the negotiated volumes. These compensations were introduced to give hospital managers some <lb/>financial security for partial coverage of their fixed costs in case of an unexpected shortfall in demand for <lb/>inpatient services. This mechanism was called &quot; flexible budgeting &quot; (Tuschen at al., 2005). <lb/>73. <lb/>The principle concept of this tapering mechanism was maintained when hospital remuneration <lb/>moved towards DRG payments from 2003 on and is still applicable. <lb/>74. <lb/>A second type of tapering – the MLA – was introduced in 2009 which is applied to all additional <lb/>negotiated hospital volume which is above the volume of the previous year. Although introduced later than <lb/>the tapering for non-negotiated revenue, it can technically be considered as the 1 st level of tapering. <lb/>Tapering rates and technical modalities of this 1 st level have been constantly changing since its <lb/>implementation. The aim of tapering for negotiated volumes has been subject to change since its <lb/>introduction in 2009. Whereas the initial objective was to limit growth in hospital expenditure 11 -in 2011 <lb/>and 2012 the MLA was supposed to generate savings by 350 Mio EUR and 270 Mio EUR respectively -<lb/>controlling the increase in hospital volumes eventually became the objective in 2013 and 2014 12 . <lb/>Evaluation of effectiveness <lb/>75. <lb/>It is difficult to assess the effectiveness of the mechanisms as the aim of their introduction <lb/>changed over time. <lb/>76. <lb/>The MLA was first introduced to limit hospital spending growth and later to disincentivise <lb/>increases in hospital volume. While the MLA did reduce spending growth to some extent in the years after <lb/>its inception, the savings would only equate to around 0.5% of total hospital costs. For the years 2013 and <lb/>2014 the savings generated via the MLA were redistributed to hospitals through an increase of the base <lb/></body>

			<note place="footnote">11 <lb/>BT 17/3360. <lb/>12 <lb/>BT 17/13947. <lb/></note>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>36 <lb/></page>

			<body>rate. Otherwise, this base rate would have decreased as a result of an increase in activity, penalising all <lb/>hospitals, including those with no or low activity increase. <lb/>77. <lb/>Table 6 shows a slowdown in the annual growth of the case-mix-volume since the introduction of <lb/>MLA in 2009 which hospitals could put forward as a proof of the positive impact of the tapering <lb/>mechanism on the reduction in volume growth. The remaining increase in hospital activity would be <lb/>triggered by medical necessity. However, health insurers would argue that this growth is still above the <lb/>increase that would be expected purely based on the demographic development (Augurzky, 2012). From <lb/>their point of view, hospitals still have an incentive to negotiate high additional volumes in their budgets <lb/>because the reduced rate of payment (25%) would only be applied for one year (two years in 2014) and <lb/>would be fully remunerated in the following year and would thus only be a weak deterrent for excessive <lb/>volume expansion. <lb/>Table 6: Rate of growth in case mix between 2004 and 2014 <lb/>Source: Own compilation based on data provided by the GKV and own research. <lb/>78. <lb/>The payment reduction of MEA for non-negotiated hospital volume is much harsher (65%) but it <lb/>does not seem to be applied at a grand scale. The tapering rate is considered high enough to discourage any <lb/>additional hospital activity beyond this point with the exception of emergency treatments. One of the <lb/>reasons for the limited application can be found in the delayed timeline of the negotiating process of the <lb/>hospital budgets. Although in theory, hospital budgets should be negotiated prospectively for a calendar <lb/>year, it is not unusual for them to begin in September of the current year. By this time, hospitals can <lb/>already project pretty accurately the hospital activity they will perform until December. The risk of <lb/>providing more than the negotiated volume -and thus having to pay the MEA-is therefore reduced. The <lb/>late hospital budget negotiations can partly be explained by delayed negotiations for the Länder base rate <lb/>which is a crucial element for the budget negotiation process. <lb/>Year <lb/>Actual Case-Mix <lb/>Change in <lb/>Case-Mix <lb/>Growth <lb/>rate of <lb/>Case-mix <lb/>Negotiated <lb/>federal <lb/>base rate <lb/>(EUR) <lb/>Rate of <lb/>growth in <lb/>federal <lb/>base rate <lb/>MLA <lb/>2004 <lb/>15 476 804 <lb/>2005 <lb/>16 033 965 <lb/>557 161 <lb/>3.60% <lb/>2006 <lb/>16 528 236 <lb/>494 271 <lb/>3.10% <lb/>2007 <lb/>17 148 731 <lb/>620 495 <lb/>3.80% <lb/>2008 <lb/>17 683 593 <lb/>534 862 <lb/>3.10% <lb/>2009 <lb/>18 084 944 <lb/>401 351 <lb/>2.30% <lb/>Negotiated rate <lb/>2010 <lb/>18 559 432 <lb/>474 488 <lb/>2.60% <lb/>2935.78 <lb/>2011 <lb/>18 764 079 <lb/>204 647 <lb/>1.10% <lb/>2963.82 <lb/>1.00% Rate set at 30% <lb/>2012 <lb/>19 101 878 <lb/>337 799 <lb/>1.80% <lb/>2991.53 <lb/>0.90% Negotiated rate <lb/>2013 <lb/>3068.37 <lb/>2.60% Rate set at 25% <lb/>2014 <lb/>3156.82 <lb/>2.90% <lb/>Rate set at 25% <lb/>with 2012 as <lb/>benchmark <lb/>volume <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>37 <lb/></page>

			<body>79. <lb/>Schreyögg et al. (2014) question in a recent study the effectiveness of the MLA in its current <lb/>form because of its indiscriminate applicability to nearly all DRG and all hospitals. The study proposes to <lb/>link the MLA with quality measures. Moreover, MLA should be more targeted to specific conditions. For <lb/>emergency treatments, such as in case of heart failure, the MLA should not be applied. Consequently, it <lb/>would then focus more on those treatments for which the strict medical necessity seems sometimes to be <lb/>more controversial (e.g. such a knee and hip replacements). The study encourages further research on the <lb/>consequence of the MLA as its impact on hospital activity and quality is still unknown. <lb/>Maryland (United States) 13 <lb/>Basic facts of health system <lb/>80. <lb/>The United States is one of the few OECD countries where public coverage of health care costs is <lb/>relatively low. The majority of Americans have private insurance that either they or their employer have <lb/>taken out. In the State of Maryland in 2013, 73.6% of the population had this type of cover compared to <lb/>64.2% in the United States as a whole. 14 <lb/>81. <lb/>The government manages the two principal public insurance schemes for low-income groups <lb/>(Medicaid and Medicare). Medicare is a federal programme for residents over 65 years of age, the disabled <lb/>and people with terminal-stage kidney disease. Medicaid, a state-based programme, covers people with <lb/>low incomes. In Maryland, 14.4% (compared to 15.6% for the United States as a whole) of the population <lb/>were insured by Medicare and 15.3% (17.3% for the US as a whole) by Medicaid. These programmes are <lb/>funded through taxation, but the beneficiaries are not covered automatically: they must sign up and, in <lb/>some circumstances, pay premiums. <lb/>82. <lb/>A substantial proportion of the entire population of the US, estimated at around 14.5% in 2013, <lb/>had no health insurance; the figure for Maryland was 10.2% (Smith and Medalia, 2014). The Affordable <lb/>Care Act adopted in 2010 seeks to gradually extend health insurance coverage, which has been compulsory <lb/>for all citizens and legal residents since January 2014. From that date, anyone who does not have sickness <lb/>insurance may be subject to a fine. 15 <lb/>83. <lb/>Private insurance coverage is heavily concentrated in Maryland as the insurer Carefirst has 66% <lb/>of the &quot; individual cover &quot; market, 73% of the small business market 16 and 70% of the large business <lb/>market. <lb/>84. <lb/>In 2009, the share of the gross domestic product of Maryland allocated to health expenditure <lb/>matched that of the United States, i.e. 15%. Annual growth in health expenditure in the State of Maryland <lb/>was equivalent to that of the whole of the United States between 1991 and 2009; for Maryland, the annual <lb/>growth was 6.6% compared to 6.5% for the United States as a whole. <lb/>85. <lb/>In 2009, per capita health expenditure was 10% higher in Maryland than in the United States as a <lb/>whole (USD 7 492 compared to USD 6 815). Several possible explanations for this include higher care <lb/>costs and a larger population covered by health insurance than the United States average. <lb/>13 <lb/>Unless otherwise stated, the statistics used for Maryland and the United States have been taken from the <lb/>Kaiser Family Foundation database (http://kff.org/). <lb/></body>

			<note place="footnote">14 <lb/>All data on health insurance coverage are extracted from US Census Bureau statistics, available here: <lb/>https://www.census.gov/hhes/www/hlthins/data/incpovhlth/2013/acs-tables.html <lb/>15 <lb/>http://kff.org/interactive/implementation-timeline/. <lb/>16 <lb/>Businesses with between 1 and 100 employees. <lb/></note>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>38 <lb/></page>

			<body>Hospitals <lb/>86. <lb/>In 2009, hospital expenditure <lb/>17 in Maryland matched that for the United States (37% and 36% <lb/>respectively), accounting for 5.5% of gross domestic product in the State of Maryland and the United <lb/>States. <lb/>87. <lb/>Total per capita expenditure for hospital services is 12% higher in Maryland than for the whole <lb/>of the United States. The total cost of hospital treatment requiring at least one night as an inpatient is <lb/>USD 2 368 per day in Maryland compared to USD 1 960 in the United States (Figure 7). <lb/>Figure 7: Expenses per inpatient day for hospital services requiring at least one night as an inpatient in <lb/>Maryland and in the United States (1999-2011) <lb/>Source: Kaiser Family Foundation database, 2014 <lb/>88. <lb/>The latest data available for the United States show that, in 2011, the bulk of hospital income <lb/>came from public funding. According to the American Hospital Association, 57.7% of hospital income <lb/>came from public programmes (39.3% Medicare, 16.3% Medicaid and 1.8% from other public programs). <lb/>Income from private insurers accounted for 34.6% of hospital receipts 18 . <lb/>17 <lb/>Hospital expenditure covers all services that hospitals deliver to patients, including accommodation, <lb/>general logistics costs, resident doctors&apos; services, medication administered in hospital, nursing care and all <lb/>services billed by hospitals in the United States. The value of hospital services is measured by total net <lb/>income comprising gross revenue less debt and charity care. (Source: http://kff.org/) <lb/>18 <lb/>Source: http://www.aha.org/research/reports/tw/chartbook/index.shtml, the remaining resources are not <lb/>attributed to any particular source of funds. <lb/>No tapering payment <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>39 <lb/></page>

			<body>89. <lb/>Bed capacity <lb/>19 in 2011 in Maryland was 23% lower than that for the United States as a whole: <lb/>There were 2.6 beds per 1 000 population in the United States compared to 2.0 per 1 000 inhabitants in <lb/>Maryland. Bed capacity in Maryland has remained steady since the 2000s, whereas it fell slightly in the <lb/>United States from 2.9 beds per 1 000 population in 2000 to 2.6 in 2011. At the same time, the number of <lb/>hospitals 20 has remained stable in Maryland and has increased slightly in the United States. Hospital beds <lb/>in Maryland are provided exclusively in private, not-for-profit hospitals. <lb/>90. <lb/>The bed occupancy rate in community hospitals 21 in the State of Maryland is nine percentage <lb/>points higher than that of the United States as a whole: in 2010, 74% of beds in Maryland were occupied <lb/>compared to 65% for the whole of the United States (National Center for Health Statistics, 2013). The <lb/>average hospital stay in community hospitals in Maryland is 4.6 days – 0.36 days less than for the whole of <lb/>the United States (4.96 days) 22 . <lb/>91. <lb/>The number of admissions in Maryland rose steadily between 2001 and 2009, and then fell <lb/>sharply (Figure 8). The number of admissions per 1 000 population rose by 12% between 2001 and 2009, <lb/>whereas the same indicator for the United States as a whole for the same period fell by 2.5%. Note that, <lb/>during that period, the tapering payment mechanism in Maryland which we will be discussed below had <lb/>been abandoned following an agreement with the hospitals. <lb/>19 <lb/>These data include beds staffed by community hospitals which account for 85% of all hospitals. Federal <lb/>hospitals, long-stay hospitals, psychiatric hospitals, institutions for the mentally handicapped and <lb/>alcoholism treatment centres are not included. <lb/>20 <lb/>The data include community hospitals which account for 85% of all hospitals. Federal hospitals, long-stay <lb/>hospitals, psychiatric hospitals, institutions for the mentally handicapped and alcoholism treatment centres <lb/>are not included. <lb/>21 <lb/>Non-federal hospitals, short-stay hospitals, specialist hospitals. <lb/>22 <lb/>Source: AHA Annual Survey of Hospitals. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>40 <lb/></page>

			<body>Figure 8: Admissions per 1 000 population between 1999 and 2011 in the State of Maryland and in the United <lb/>States <lb/>Source: Kaiser Family Foundation database, 2014 <lb/>Hospital payments in the State of Maryland <lb/>Main features of hospital payment <lb/>92. <lb/>The way hospitals are paid in the United States generally differs according to the different payers. <lb/>For Medicare this is typically DRG-based but along with a number of other states, Maryland obtained a <lb/>waiver which permitted them to implement an alternative payment system in its dealings with Medicare 23 . <lb/>The same year, in 1977, Maryland went a step further and implemented an all-payer model which means <lb/>that all insurance schemes have to apply the same payment system. Hospital tariffs are determined by the <lb/>Health Services Cost Review Commission (HSCRC) 24 for all hospitals and are not negotiated between <lb/>23 <lb/>In the mid-70s, Medicare was keen to experiment with new forms of hospital payment. Maryland and a few <lb/>other States (New York, New Jersey, Massachusetts, West Virginia and Washington) applied for waivers <lb/>from the national Medicare and Medicaid system so that they could instead put in place their own state-<lb/>devised systems to cover the categories of population insured by Medicare and Medicaid. Maryland was <lb/>the first State to obtain that waiver in 1977. <lb/>24 <lb/>Since its establishment, the HSCRC has been thoroughly independent. From a legal point of view, it is <lb/>accountable to the state governor and not the US Secretary of Health. Consequently, the Health Department <lb/>has only a limited degree of administrative control over it (mainly linked to personnel). Additionally, the <lb/>HSCRC has economic independence because it is funded by a surcharge on the hospital tariffs paid by <lb/>insurers. Finally, it is governed by a board of seven delegates who must agree to sit on a voluntary basis. <lb/>The principal task of the HSCRC was to study and approve inpatient tariffs. In doing so, the HSCRC is <lb/>required to ensure that the total costs of all services provided by a hospital are reasonable, that the <lb/>110 <lb/>112 <lb/>114 <lb/>116 <lb/>118 <lb/>120 <lb/>122 <lb/>124 <lb/>126 <lb/>128 <lb/>1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 <lb/>Discharges <lb/>per <lb/>1,000 Population <lb/>United States <lb/>Maryland <lb/>No tapering payment <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>41 <lb/></page>

			<body>insurers and hospitals. Thanks to this, Maryland has been able to implement innovative tariff policies in <lb/>hospitals. <lb/>93. <lb/>The decisive factor for hospital payment is the approved revenue budget. The revenue budget is, <lb/>theoretically, the product of the pre-defined allowed total charges per case and the different cases <lb/>(classified in DRG). The allowed total charge per case is calculated by the HSCRC. To do this the HSCRC <lb/>sets a unit rate per cost item for each hospital. There are around 50 cost items per hospital. Examples of <lb/>cost items are intensive-care units, operating theatres, radiology, emergency departments, clinical <lb/>laboratories, etc. <lb/>94. <lb/>In order to set unit rates per cost item, the HSCRC collects detailed data on costs using an <lb/>accounting system that assesses costs based on activity and allocates direct and indirect costs to each <lb/>revenue item. Hospitals are required to supply data on costs if they want to be eligible for reimbursement <lb/>under Medicare. The data make it possible to calculate costs by day for each cost centre. <lb/>95. <lb/>The unit rates are then adjusted to take account of the diversity of patients in each hospital <lb/>notably on the basis of the location of the hospital and the proportion of patients from each ethnic group. <lb/>They also take labour market differences into account. The allowed total charges per case (tariff) is the <lb/>sum of the product of the unit rates and the units used for each cost item involved in the treatment process <lb/>of one case. So tariffs for the Johns Hopkins Hospital, a teaching hospital based in Baltimore, Maryland, <lb/>are not the same as those for a rural hospital. There is also a fund to mutualise the costs of care provided to <lb/>uninsured patients. This fund reimburses hospitals for such treatment. <lb/>96. <lb/>The unit rates of inpatient activities in all hospitals are updated every year. The update factor is <lb/>dependent on several key elements. First, the HSCRC uses an indicator that reflects the rise in the costs of <lb/>factors of production published by Medicare, known as the market basket index. Then, the Commission <lb/>has discretion to increase the update factor in order to boost hospitals&apos; profitability, for example, to <lb/>encourage capital investment, or to reduce that factor in line with assumed productivity gains in the <lb/>hospital sector or to comply with the constraints associated with the Medicare waiver test. The update <lb/>factor is the same for all hospitals, although certain programmes can influence the final update factor that <lb/>the hospital will enjoy (Murray, 2014). Consequently, the allowed total charges per case change every year <lb/>reflecting the change in the different unit rates. <lb/>Hospital revenue budgets <lb/>97. <lb/>As discussed, the decisive factor for hospital managers is the revenue budget defined by the total <lb/>number of cases (classified into DRG) and the allowed total charges per case based on the different unit <lb/>rates for the different cost centres. The unit rate system is very disaggregated, and the cost-centre approach <lb/>makes it similar to a fee-for-service system. When the HSCRC tried to constrain growth in hospital costs <lb/>by capping the update factor of the several unit rates, hospitals were able to increase their income by <lb/>increasing cost centre volume (more tests, longer inpatient stays, etc.). <lb/>98. <lb/>The HSCRC retained the unit rate structure but it enforced a DRG 25 constraint on hospital <lb/>revenues. Each hospital has a target amount of revenue per DRG (allowed total charges) summed up for all <lb/>DRGs that it can earn during the course of a year. It charges tariffs for all patients but it has to monitor <lb/>hospital&apos;s overall receipts are reasonably in line with its total costs and that its tariffs are fairly distributed <lb/>across all hospital service purchasers. <lb/>25 <lb/>Each hospital admission is grouped into one of 320 &quot; All Patient Refined Diagnosis Related Groups &quot; (APR-<lb/>DRGs) that classify patients into clinically cohesive categories based on their medical condition and the <lb/>severity of their illness. The 320 APR-DRGs are separated into four &quot; severity of illness &quot; levels. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>42 <lb/></page>

			<body>how it is doing on average relative to these DRG constraints. It can do this in an aggregate way by <lb/>monitoring its overall case mix adjusted charge per case. If it is over the pre-established target case mix <lb/>adjusted charge per case established for it, it must lower its allowed total charges during the year to come <lb/>back into compliance. It does so because the HSCRC can assess very large penalties for over-charging. <lb/>99. <lb/>Hospitals are not required to invoice by unit rate or by treatment episode at the rates set by the <lb/>HSCRC. For any care episode, a hospital can set its own tariffs to better reflect its actual use of resources <lb/>and production costs in a particular case. However, at the end of the year, the hospital is required to invoice <lb/>insurers for the total authorised budget equal to the product of the fixed charge per care episode and the <lb/>case mix. To do so, the hospital must offset any overbilling compared to HSCRC charges by invoicing for <lb/>a lower price over the year per cost centre or by lowering the resources used. The tolerance for change in <lb/>unit rates must be between ±5% of unit rates set by the HSCRC. <lb/>Tapering payment or variable cost factor (VCF) in the State of Maryland <lb/>Technical considerations <lb/>100. <lb/>Tapering payment was introduced alongside DRG-based payments in hospitals in 1977. There is <lb/>no difference in the way tapering is applied to the various types of inpatient services. At the same time, <lb/>hospital representatives are able to apply for exemptions especially if they open new operating theatres or <lb/>make new capital investments. <lb/>101. <lb/>Although the conclusions from empirical assessments of hospitals&apos; cost structure to identify <lb/>economies of scale are somewhat unclear, the HSCRC was convinced that, in a large hospital, variable <lb/>costs could be as high as 50% or even 60%. Consequently, Maryland implemented a tapering payment <lb/>called variable cost factor (VCF). Any increase in activity beyond the revenue budgets is now billed at <lb/>50% of the tariff in force for hospitals under this system. In addition to tapering, set at a rate of 50%, this <lb/>system imposes two further constraints on hospital volumes, namely the volume governor and the case-mix <lb/>governor. The former restricts growth in hospital volumes to 2% per year. The latter restricts growth in <lb/>hospital case mix in 2014 to 0.5%. <lb/>102. <lb/>Over the year, hospitals must measure trends in volumes and the impact that tapering payment <lb/>might have on those trends in terms of their tariffs and final income. They must try to adjust their unit rates <lb/>or the intensity of services for a treatment during the year under way. Hospitals have an information <lb/>system to help them adjust their tariffs and to keep them, most of the time, close to the final tariffs once <lb/>tapering has been taken into account and, therefore, close to the authorised revenue. In the event of a <lb/>difference, the allowed total charges are adjusted downwards or upwards the following year. <lb/>103. <lb/>From a dynamic point of view, where changes over time are concerned, revenue authorised for <lb/>year t+1 before tapering payment can be applied is defined in two ways: <lb/> Where activity increases compared to the revenue authorised in t: the revenue authorised for <lb/>year t+1 equals the revenue authorised by the HSCRC in t plus the share of variable costs <lb/>engendered by the increase in activity. Thus, if a hospital had an authorised revenue of 100 in t <lb/>and records a revenue of 110 in t+1, then the authorised revenue for year t+1 equals 100 plus the <lb/>share of variable costs linked to the 10 points of supplementary revenue i.e. 6 where the VCF is <lb/>60%. <lb/> Where activity falls compared to the revenue authorised in t: the revenue authorised for year t+1 <lb/>is equal to the receipts registered in t, plus the fixed costs engendered by the receipts that should <lb/>have been received in t. So, if a hospital had an authorised income of 100 in t and records a <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>43 <lb/></page>

			<body>revenue of 90, the revenue authorised for year t+1 is equal to 90 plus the share of fixed costs <lb/>linked to authorised revenue of 100 i.e. 4 where the VCF is 60%. <lb/>Rationale behind the tapering system <lb/>104. <lb/>The rationale behind the introduction of the variable cost factor (VCF) was to capture the <lb/>marginal revenue from rising hospital volumes. <lb/>105. <lb/>From 1977, hospitals received only 50% of the tariff set by the HSRC for any incremental <lb/>increase in volumes above the activity cap. Tapering payment neutralised any incentive to increase <lb/>activity. However, tapering is not only a means of regulating volume growth. It can also protect hospitals <lb/>against dips in activity. If hospital volumes fell, the hospital received 50% of the amount of the drop in <lb/>volume so that it could cover its fixed costs. <lb/>106. <lb/>In the early 1990s, the HSCRC gradually reduced regulation of hospital volumes through <lb/>tapering scales. So as to allow hospitals to generate greater revenue and increase their profitability, <lb/>tapering scales were abolished for certain hospitals (Johns Hopkins and University of Maryland, the two <lb/>major teaching hospitals) and were fixed at 15% for the rest. The 15% rate was determined so that <lb/>hospitals could generate greater receipts and thus increase their profitability. Additionally, the fall in the <lb/>rate was intended to allow hospitals to implement investment policies. <lb/>107. <lb/>Between 2001 and 2008, tapering payment was abolished with the hope that managed care could <lb/>help containing costs. A significant growth in volumes was observed in Maryland between 2001 and 2008. <lb/>In response to that increase, the tapering payment system was reintroduced with the scales again at the <lb/>levels they were in the 1980s. <lb/>Evaluation of effectiveness <lb/>108. <lb/>Firstly, hospitals have altered the way they manage their activities as a result of tapering so as to <lb/>remedy the unintended effects of self-employment by practitioners who are paid through a fee-for-service <lb/>mechanism. Indeed, physicians, especially surgeons, have a vested interest in increasing services because <lb/>their income is a function of the services they deliver. At the same time, hospitals must comply with the <lb/>constraints imposed by tapering. Thus hospitals have established teams responsible for risk management <lb/>within their hospitals to control self-employed practitioners&apos; activities. These controls cover, in particular, <lb/>the relevance of treatments delivered by health professionals and the average length of an inpatient stay. <lb/>109. <lb/>Secondly, the rise in hospital volumes after the abolition of tapering in 2001 hints that tapering <lb/>has had an effect at least on hospital volume. Kalman (2014) shows a significant increase in the volume of <lb/>inpatient admissions, outpatient visits and operating costs following the abolition of tapering between 2001 <lb/>and 2008. Once tapering was removed in 2001, admissions and outpatient consultations rose by 7.7% and <lb/>17.1% respectively – a significant increase compared to the preceding years. The yearly rate of growth in <lb/>admissions rose significantly when tapering was abolished, from 0.8% between 1991 and 2001 to 2.4% <lb/>between 2001 and 2008. Similarly, hospital operating costs rose relatively sharply: the annual growth rate <lb/>for operating costs increased from 4.8% between 1991 and 2001 to 8.4% between 2001 and 2008. Costs <lb/>therefore grew more quickly than volumes. This study shows that hospitals react to changes in financial <lb/>incentives. Kalman&apos;s study (2014) concludes that tapering can act as a model to constrain growth both in <lb/>hospital volumes and in costs within the hospital sector. <lb/>110. <lb/>However, the sharp growth in hospital volumes (admissions, readmissions, emergency visits, <lb/>outpatient care) over the period 2001 to 2008 led the HSCRC to introduce several plans to change the way <lb/>hospitals were paid in recent years. These included: progressive switch to global budgets for hospital <lb/>payment; reintroduction of the tapering system; and performance-based payments for hospitals. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>44 <lb/></page>

			<body>111. <lb/>To date, 93% of hospitals are remunerated under a global budget system. The tapering payment <lb/>system therefore now applies only to 7% of hospitals. The fact that so few hospitals opted for tapering <lb/>payment over the global budget system can be explained by the very tight restrictions on hospital activities <lb/>for hospitals that choose tapering. <lb/>112. <lb/>The reason behind the decision to promote the global budget system is that it seeks to exercise <lb/>stricter control over the growth in hospital volumes and thereby ensure that growth in hospital costs <lb/>matches growth in Maryland&apos;s wealth. In the past, growth in hospital costs have been 2 to 3 points higher <lb/>than growth in the State&apos;s wealth. This meant sharp growth in health expenditure as a share of GDP from <lb/>7% in 1970 to 15% today. The HSCRC is attempting to rein in growth in per capita spending to match the <lb/>growth in GDP in Maryland over the past 10 years, namely 3.58%. That is now the cap on growth in the <lb/>hospital sector. <lb/>Czech Republic <lb/>Basic facts of the health system <lb/>113. <lb/>Mandatory health insurance was introduced in 1991 in the Czech Republic (Kinkorová et al., <lb/>2012). All permanent residents in the Czech Republic are entitled to health care coverage, while <lb/>non-permanent residents are also covered if they are working for a Czech employer (Bryndová et al., <lb/>2009). Residents who are not in these two situations must take out private insurance to cover their care <lb/>costs. The benefit basket includes outpatient consultations, analyses and diagnoses, inpatient stays, <lb/>rehabilitation, transport and preventive care (Kinkorová et al., 2012). <lb/>114. <lb/>To receive these services, permanent residents must sign up with one of the seven social health <lb/>insurance funds. Residents are free to choose the insurer and may change insurer each year. In 2008, <lb/>however, only 2.1% of the insured population chose to change insurer because competition between the <lb/>various providers is poor (Bryndová et al., 2009). Risk selection by insurers on contracts for basic services <lb/>is not permitted. <lb/>115. <lb/>There are two sources of funding for social health insurance funds: social contributions from <lb/>employers and employees (76%) and state contributions for inactive insured persons (24%). <lb/>Hospitals <lb/>116. <lb/>Hospital costs in the Czech Republic were lower than the OECD average in 2011 at 2.3% of GDP <lb/>compared to 2.6%. However, the volume of activity in the Czech Republic is 30% greater than the OECD <lb/>average in terms of numbers of admissions per 1 000 population. <lb/>117. <lb/>Hospital services are funded principally by social security, which funds 94% of hospital costs, <lb/>while the general government funds 3%. Private insurance and direct payments from households each <lb/>account for 3% of funding for hospital costs. Private out-of-pocket expenditure in the Czech Republic is <lb/>defined by a co-payment of EUR 4 per day. <lb/>118. <lb/>Hospital capacity in the Czech Republic is among the largest in the OECD countries. With <lb/>6.8 beds per 1 000 population, the Czech Republic ranks seventh in the OECD and is above the OECD <lb/>average (4.9 beds per 1 000 population). However, the number of beds fell sharply between 2000 and 2011 <lb/>in the Czech Republic (down by 10%), which compares with a 5% reduction on average across the OECD <lb/>over the same period. <lb/>119. <lb/>Public hospitals are the main suppliers, with 86% of beds, compared to an OECD average of <lb/>73%. The central and regional governments own and manage most public hospitals. Except for cases of <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>45 <lb/></page>

			<body>emergency, a patient must choose a hospital that has a contract with his insurer. In practice, all insurance <lb/>funds have contracts with the main hospitals, and there are therefore few restrictions. <lb/>120. <lb/>There is no explicit regulatory system in the Czech Republic governing how provision of hospital <lb/>services are organised. For government-owned public hospitals, however, the authorities control changes in <lb/>hospital bed capacity and investment in expensive technologies. There is also an intrinsic limitation for the <lb/>expansion of hospital capacity by the requirements for hospitals to have contracts with insurers. Insurers <lb/>therefore have the power to restrict unjustified capacity expansion. <lb/>Hospital payments in the Czech Republic <lb/>Main features of the DRG payment system <lb/>121. <lb/>According to Ministry of Health estimates, 80% of hospital receipts for medical, surgical and <lb/>obstetric care come from DRG-based payments. The remaining 20% of hospitals&apos; revenue relate to other <lb/>activities and are subject to bilateral agreements between insurers and hospitals. <lb/>122. <lb/>Until 2007, the principal means of payment for hospitals was a global budget system. In 2008, <lb/>some services were reimbursed through DRG-based payment but revenues for each hospital could differ by <lb/>only 1% (above or below) of the amount that would have been paid under the global budget. This range <lb/>was referred to as the &quot; risk corridor &quot; . Thus, initially, the expected hospital volumes were determined using <lb/>the historic volumes which were used to define the prospective global budgets (as was the case before <lb/>2008). The total revenue based on DRG-based payments for the same volume of care was then calculated. <lb/>If this amount was outside the risk corridor then the hospital was paid by global budget. <lb/>123. <lb/>Since 2009, activity-based payment (DRG) has been the predominant payment system for <lb/>hospital activity and the risk corridor no longer exists. It replaced the global budget and has been used <lb/>since that date (except for the year 2011 when global budget was re-introduced for one year). The <lb/>classification is based on International Refined-DRG and adjusted to fit Czech circumstances. There are <lb/>approximately 1 000 DRGs associated with relative cost weights. DRG weights include costs for <lb/>medications, medical devices and physicians&apos; salaries. <lb/>124. <lb/>Some hospital services are remunerated via alternative mechanisms such as fee-for-service or <lb/>specified budgets for certain rare diseases in some particular hospitals. Additionally, psychiatric care, <lb/>rehabilitation and some patient groups where cost variability is too high are excluded from DRG-based <lb/>payment. Psychiatric and rehabilitative care, for example, is paid on a fee-for-service basis. <lb/>Hospitals reimbursement base rate <lb/>125. <lb/>The DRG payments from insurers for the provision of inpatient services are determined by a <lb/>DRG weight multiplied by a base rate. Theoretically, hospitals and insurers are free to negotiate this base <lb/>rate but in practice, it is decided centrally. The Minister for Health sets out the base rate in an annual <lb/>decree published in December of the previous year. <lb/>126. <lb/>The principal parameter in determining the base rate in the hospital sector is the projected ability <lb/>for health insurers to pay for hospital services via their revenues from social insurance contributions. There <lb/>is no single base rate for all hospitals, however. During the transition from the global budget to the DRG-<lb/>based system, hospital-specific base rates were defined to mitigate the effects of transition. These <lb/> &quot; individual &quot; base rates are converging towards a single base rate. Consequently, each year, the public <lb/>decree also sets out the rules on base rate convergence. The variation in hospital base rates has decreased in <lb/>recent years. In 2014, the convergence has been completed at the hospital level as each hospital applies a <lb/>single base rate to all insurers. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>46 <lb/></page>

			<body>The tapering payment system in the Czech Republic <lb/>Technical consideration <lb/>127. <lb/>Almost all activities are subject to tapering payment beyond a pre-defined threshold. As <lb/>explained previously, a few activities were withdrawn from DRG-based payment because of the huge <lb/>variations in costs between cases within a single DRG. Such care, however, is also subject to tapering <lb/>payment, although the actual payment is calculated differently. There may be exceptions as a result of <lb/>bilateral agreements between insurers and hospitals, the details of which are difficult to access. <lb/>128. <lb/>The Ministry of Health determines the formula used to set the activity caps (expressed in terms of <lb/>case mix) above which tapering applies. Caps are set for each hospital-insurer pair. Thus, each hospital has <lb/>to consider separate activity caps for the billing of services to each individual insurer. It is not the total <lb/>volume produced by a hospital that is decisive for the application of tapering but the volume provided for <lb/>each insurer. The formula changes each year because the Ministry tries to ensure that the system is <lb/>financially balanced (see Annex 3 for a detailed description of the formula used in 2013). <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>47 <lb/></page>

			<body>129. <lb/>The tapering payment mechanism can be broken down into two main steps: <lb/> Step 1: A cap is set centrally for growth in activity between t-2 and t, expressed in terms of the <lb/>ratio volume t /volume t-2 but also taking into account the change in the number of admissions so as <lb/>to control risks of upcoding. In 2011, the cap was set at 98% of the volume for the benchmark <lb/>year (representing a 2% fall in volumes). In 2012, the cap was set at 115% of the case mix for <lb/>2010 (an increase of 15%). At the same time, a lower trigger threshold for tapering was set for <lb/>hospitals where activity, adjusted for case mix, was between 105% and 115% of that of the <lb/>preceding year but where the number of admissions had fallen. This mechanism sought to <lb/>discourage hospitals from &quot; upcoding &quot; their activities. <lb/> Step 2: Hospital revenue is defined for each contract between each individual hospital and each <lb/>insurer (i.e. more than 1 000 contracts), as follows: <lb/> Hospital volumes in year t are estimated and compared to those for year t-2; <lb/> This volume growth is benchmarked with the centrally set cap (115 in year 2012 <lb/>26 ); <lb/> The change in a hospital&apos;s &quot; regulated case mix &quot; (Vol t /Vol t-2 ) cannot be greater than the <lb/>centrally set cap (1.15 in year 2012). The regulated case mix is therefore equal to the <lb/>minimum of Vol t /Vol t-2 and 1.15. <lb/> The &quot; regulated case mix &quot; is then multiplied by the hospital&apos;s base rate to establish the <lb/>revenue that the insurer must pay the hospital. <lb/> In 2012, two caps were in force: hospitals received only 50% of the tariff per case beyond the <lb/>first cap (105%) and were not paid at all for activities beyond the second cap (115%). <lb/>130. <lb/>In practical terms, hospitals receive advances at the beginning of each month based on the <lb/>reimbursement levels for preceding years. The total amount paid by an insurer to a hospital is therefore <lb/>known only at the end of the period. Consequently, the amount of tapering is calculated ex post, and it <lb/>takes the form of reductions on future hospital activities billed to that insurer. In practice, at the end of the <lb/>year, an adjustment is made and, where necessary, hospitals repay the insurers over the next quarter <lb/>(between April and June). All calculations are made by insurers, but the hospital may raise an objection in <lb/>case of disagreement. <lb/>Rationale of introduction <lb/>131. <lb/>The tapering payment mechanism was introduced alongside DRG-based payment in 2009 to <lb/>prevent inflationary effects during the shift to DRG-based payment and to attenuate the impact of <lb/>transition. With the economic crisis and the need to control rising costs, the tapering system remained in <lb/>use after the transition period, except in 2011 when global budget was reintroduced for one year. However, <lb/>in 2014 the government decided to move back to hospital financing via prospective global budgeting. <lb/>Evaluation of effectiveness <lb/>132. <lb/>The impact of tapering on volume growth is not obvious (Figure 9). Between 2009 and 2010 <lb/>when the tapering system was introduced –together with DRG payments-, the overall case mix for all care <lb/>remunerated on a DRG basis rose by nearly 15%. The Ministry of Health noted a slight fall in the case mix <lb/>26 <lb/>A single cap has been used to simplify matters. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>48 <lb/></page>

			<body>in 2012 but did not link it to tapering. Indeed, in 2011, the Czech Republic reintroduced a global budget <lb/>before reverting to tapering in 2012. <lb/>133. <lb/>Actually, the tapering mechanism was not expected to contain volume growth in the long term. <lb/>As the case mix in year t was used as the benchmark for calculating the cap two years later, hospitals still <lb/>had a strategic interest in increasing their volumes. This may, in part, explain why the Czech Republic <lb/>reverted to the global budget in 2014. <lb/>Figure 9: Total case mix for care between 2007 and 2012 <lb/>Source: Czech Ministry of Health <lb/>Israel <lb/>Basic facts of health system <lb/>134. <lb/>Israel is a country where basic health coverage is provided via social health insurance. Since <lb/>1995, all permanent residents of Israel have been entitled to access to the services listed under the National <lb/>Health Insurance (NHI) Act. This basket of care includes outpatient consultations, analyses and diagnoses, <lb/>inpatient and rehabilitative care (Bowers, 2014). To receive these services, permanent residents are <lb/>required to sign up with one of the four Social Health Insurance funds (SHI funds). Risk selection of <lb/>clients for contracts that cover basic services is not permitted. <lb/>135. <lb/>Revenues of SHI funds are generated from two sources: a payroll tax, set by law, and general <lb/>taxation. Insurers cannot adjust contributions in line with their financial situation. There are exemptions <lb/>and rate reductions for various groups of the population such as pensioners and recipients of replacement <lb/>income. All revenues are collected by the National Insurance Institute (NII) distributing them to the four <lb/>SHI funds. <lb/>Hospitals <lb/>136. <lb/>Hospital expenditure in Israel accounted for 1.9% of GDP in 2009, lower than the OECD average <lb/>(2.6% of GDP). <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>49 <lb/></page>

			<body>137. <lb/>On average, 59% of expenditure on hospital services is funded by social security (the four <lb/>insurers), 33% by the State, 5% by corporations and 2% directly by households. These out-of-pocket <lb/>expenditures are not co-payments since acute hospital services are free at the point of delivery; they <lb/>include payments for services which are not included in the basic health care basket. <lb/>138. <lb/>One of the features of hospital provision in Israel is the low number of beds. There are 3.3 beds <lb/>per 1 000 population, ranking Israel 19 th among OECD countries for this indicator. The average number of <lb/>beds in OECD countries is 4.9 per 1 000 population. The number of beds remained stable between 2000 <lb/>and 2011 in Israel (+0.5%), whereas it fell by 5% on average throughout the OECD. Only 58% of <lb/>hospitals beds are dedicated to curative care which is below the OECD average. However, at 198, the <lb/>number of hospital discharges per 1 000 population for Israel is 28% higher than the OECD average of <lb/>155. <lb/>139. <lb/>Most hospital beds in Israel are public: 85% of beds are in public hospitals compared to an <lb/>average of 73% in the OECD countries. The private hospitals are either managed by one of the four <lb/>principal insurers, forming part of a health maintenance organisation, or by private independent businesses. <lb/>The patient is free to choose the hospital he attends, although there are incentives to guide him in the form <lb/>of agreements between hospitals and health insurer. <lb/>140. <lb/>The government has a strong influence on how hospital provision is organised and its main <lb/>features. It decides on the number of beds and the type of activities for which they are earmarked in both <lb/>public and private sectors. Similarly, investment in costly technologies such as medical imaging is <lb/>regulated by local governments for hospitals that enter into contracts with the four social health insurers. <lb/>Hospital payments in Israel <lb/>141. <lb/>Hospitals are financed either by activity-based payments or by a per diem. The activity-based <lb/>payment system is different from that commonly used in other OECD countries. In Israel, it refers to <lb/>procedures rather than to diagnoses. These payments were introduced in the 1990s to reduce waiting lists <lb/>for 30 relatively costly interventions. In 2009, the payments covered 150 interventions and accounted for <lb/>an average of around one-third of hospital revenues, with strong variations across hospitals. They currently <lb/>cover 240 procedures and account for 38% of care revenues in hospitals. <lb/>142. <lb/>Per diem payments apply to most inpatient stays. They account for 35% of hospital budgets and <lb/>62% of payments for inpatient care. Per diem payments are set according to speciality but also by type of <lb/>care (intensive, etc.). There are 46 different per diem hospital payments. <lb/>143. <lb/>Hospital payments are regulated by law only for the public sector. Therefore, the tariffs for <lb/>procedure-based payments and per diem drawn up by the Ministry only apply in public hospitals. Most <lb/>private hospitals use these tariffs as well, although there is no legal requirement for them to do so. The <lb/>tariffs of the various services are updated twice a year by a committee including representatives of the <lb/>Ministries of Finance and Health, the insurers and hospitals. Tariffs must be revised without changing the <lb/>overall budget. Any increase in tariffs for a procedure or the introduction of a new service must therefore <lb/>be to the detriment of another procedure. The tariffs define the maximum amount that hospitals can invoice <lb/>for the provision of a service. <lb/>The tapering payment system in Israel <lb/>Technical considerations <lb/>144. <lb/>Tapering payments apply to payments made by public insurers to public hospitals. The scope of <lb/>tapering has been expanded since it was introduced. It originally applied only to activities at public <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>50 <lb/></page>

			<body>hospitals owned by the government, but, since 2008, tapering has been expanded to cover public hospitals <lb/>owned by health insurers. Expenditures covered under private insurance coverage are not considered at all <lb/>in this scheme. <lb/>145. <lb/>Every year, the government determines parameters for the tapering system (budget caps and tariff <lb/>reductions) but these parameters only apply &quot; by default &quot; when no bilateral agreement has been signed <lb/>between a hospital and a SHI fund. The general rule is that payments for hospital activities are governed by <lb/>individual contracts between SHI funds and hospitals. The tapering system drawn up by the government <lb/>applies only to 10% of cases. However, the structure of the tapering system introduced by the government <lb/>strongly influences the structure of the individual contracts between hospitals and SHI funds. <lb/>Default system in 2014: under the legal framework, tapering payment affects only 10% of activities <lb/>146. <lb/>Tapering covers most activities paid through per diem or procedure-based payments, with some <lb/>exceptions (e.g. psychiatric care). <lb/>147. <lb/>In practice, the following principles apply to each hospital and insurer in 2014. Contracts <lb/>between each hospital and insurer in 2012 determine the Gross Revenue Cap (GRC), or the total amount <lb/>billed for treatments at national tariffs, and the Net Revenue Cap (NRC), which equals the GRC minus <lb/>discounts agreed during negotiations between the insurer and the hospital. At the same time, adjustments <lb/>are allowed so as to take into account changes in prices in the hospital sector, demographic trends and bed <lb/>capacity <lb/>27 . If the hospital exceeds the Gross Revenue Cap stated in the contract, then hospitals are <lb/>remunerated at a reduced rate. <lb/>148. <lb/>Israel&apos;s tapering payment system employs several caps and tapering rates (Table 8): for any <lb/>activities that exceed the hospital cap by up to +2%, insurers pay only 70% of the price negotiated the <lb/>previous year by hospitals and funds. They then pay 33% of the negotiated price for overshoots of between <lb/>102% and 113% of the negotiated volume, and finally 65% of the negotiated price beyond 113%. <lb/>149. <lb/>The 33% rate was apparently chosen to reflect the difference between a hospital&apos;s total charges <lb/>and its wage bill, which in Israel is close to 70%. From the hospitals&apos; point of view, it was necessary to set <lb/>a tapering rate that did not act as a disincentive for the delivery of care. From the insurers&apos; point of view, <lb/>the rate had to be low enough to increase their negotiating power. <lb/>150. <lb/>The tapering mechanism also protects hospitals against any significant drop in volume of <lb/>activities (Table 7). Regardless of its level of activity, a hospital is guaranteed to receive 95% of the Net <lb/>Revenue Cap. The hospital also receives 30% of the payments it would have received for undelivered <lb/>services representing 95%-100% of the Gross Revenue Cap, in other words for services up to the tapering <lb/>threshold (Table 7). <lb/>27 <lb/>The Ministry of Health and the Ministry of Finance first updates hospitals&apos; activity caps in 2012 in line <lb/>with two key parameters: the increase in the number of persons insured by the SHI funds, and the historic <lb/>payment patterns for hospitals (price and quantity) for each SHI funds. Projected changes in these <lb/>parameters are based on trends over the previous five years. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>51 <lb/></page>

			<body>Table 7: The tapering payment mechanism in Israel <lb/>Remuneration of activities above the Gross <lb/>Revenue Cap <lb/>Remuneration of activities if the Gross Revenue <lb/>Cap is not reached <lb/>Cap reached <lb/>All activities paid with <lb/>agreed discounts = Net <lb/>Revenue Cap <lb/>If activities are less <lb/>than 95% of the cap <lb/>Guaranteed income of 95% of <lb/>the Net Revenue Cap <lb/>Overshoot of 0-2% <lb/>70% of the negotiated <lb/>price <lb/>Activity of between <lb/>95% and 100% of the <lb/>Gross Revenue Cap <lb/>Payment of 95% of the Net <lb/>Revenue Cap <lb/>+ <lb/>30% for undelivered activities <lb/>between 95% and 100% of the <lb/>Gross Revenue Cap <lb/>Overshoot of the cap by <lb/>between 2% and 13% <lb/>33% of the negotiated <lb/>price <lb/>Overshoot of the cap by more <lb/>than 13% <lb/>65% of the negotiated <lb/>price <lb/>Tapering as part of negotiations between insurers and hospitals <lb/>151. <lb/>Each time the government publishes a new tapering system (i.e. new activity thresholds and new <lb/>tariff reductions), hospitals begin negotiations with the main insurers. The government publishes <lb/>guidelines that take into account previous contracts between hospitals and SHI funds and define the <lb/>reductions that apply over and above specific volumes of hospital activity. Outside this legal framework, <lb/>SHI funds and hospitals can negotiate specific tariff reductions or reduced waiting times for their insurees. <lb/>Whilst hospitals and insurers are not required to take into account the default framework decreed by the <lb/>government, all contracts that are negotiated are required to comply with the minimum activity levels that <lb/>must be paid for by the insurer to the hospital. In 2014, therefore, an insurer that has a contract with a <lb/>hospital is required to pay at least 95% of the amount it paid to the hospital in 2012. <lb/>152. <lb/>The system introduced by the government is the starting point for negotiating contracts between <lb/>insurers and hospitals. In practice, in the case of the SHI fund &quot; Clalit &quot; , a representative negotiates with <lb/>hospitals in each district. 28 Each district representative knows the budget per capita, adjusted for case <lb/>severity, that he is authorised to negotiate with all hospitals. The three principal parameters discussed <lb/>during negotiation are the global budget before discounts, discounts and, finally, quality of care including <lb/>waiting times. The representative and hospital negotiate on the basis of services delivered in the previous <lb/>year and take account of overall trends in volume estimated by the government. Epidemiological trends are <lb/>not taken into account during the negotiations. <lb/>153. <lb/>The degree of tapering negotiated in bilateral contracts can be high. According to the Ministry of <lb/>Health, the difference between the prices set by the committee and the prices negotiated can be explained <lb/>by the fact that the prices set by the committee take into account variable and fixed costs of production. <lb/>28 <lb/>A district is an administrative division below central government and above municipalities. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>52 <lb/></page>

			<body>During negotiations, SHI funds can negotiate discounts as a function of negotiated volumes by paying only <lb/>for variable costs. <lb/>154. <lb/>The contracts concluded between SHI funds and hospitals set out two types of reduction. The <lb/>first is a system-wide reduction in the tariff for hospital services applicable to all activities. The second <lb/>applies above a specified level of activity (tapering). The average discount negotiated is 19.4%. This <lb/>discount can be (artificially) expressed according to three components: a system-wide reduction of 2% <lb/>applied on all hospitals, that takes account of the general increase in hospital volumes; a &quot; theoretical &quot; <lb/>reduction representing the reduction that the insurer would have received under the tapering system laid <lb/>down by the Government, which is on average 10%; and, finally, the reduction obtained by the insurer as <lb/>part of its negotiations with the hospital, on average 7.4%. <lb/>155. <lb/>Some services are excluded from the tapering payment system. If a hospital wants to introduce a <lb/>new activity, then that activity is not taken into account during negotiations on the capping system. <lb/>Moreover, if a hospital wants to develop a particular activity, for example MRI scans, the SHI fund can <lb/>seek significant discounts in exchange for volume growth. If the SHI fund wants to offer a particular <lb/>quality of service to its insurers, such as reduction in waiting times for certain procedures, it may agree to <lb/>smaller reductions in exchange for better quality of service. <lb/>156. <lb/>In practice, tapering is applied to charges in the current year. Using the monthly invoices sent by <lb/>the hospitals, the SHI funds decide whether the monthly demand for payments is in line with the expected <lb/>monthly payment given the cap set by the government or during negotiations. If the monthly invoice <lb/>exceeds the expected amount, the SHI funds subtract a proportion of the reduced tariff that was negotiated. <lb/>Each month, the SHI funds take account of previous payments to balance out this system of adjustments to <lb/>charges. <lb/>Rationale of introduction <lb/>157. <lb/>Tapering payment was introduced in 1994 at the same time as the Health Insurance Act that made <lb/>health coverage universal in Israel. Upon introduction, the aims of tapering were twofold: to constrain <lb/>growth in the use of hospital services and to reduce insurers&apos; expenditure on services above the cap. It was <lb/>intended to provide some protection to SHI funds which feared that provision of health insurance for the <lb/>whole population would lead to an explosion in health expenditure in general, and hospital costs in <lb/>particular. <lb/>158. <lb/>Tapering payment has been in a state of continuous change since it was introduced. Between <lb/>1994 and 1997, the revenue cap above which tapering applied was an absolute maximum: the hospital <lb/>received no further payment at all once the cap had been reached. Between 1997 and 2005, SHI funds paid <lb/>only 50% of the charge for services above the cap. At the time, this rate was accepted as a reasonable <lb/>estimate of the variable proportion of hospital costs. However, insurers were suspected of concentrating <lb/>inpatient treatment for their insurees on just one hospital, so as to reduce the cost of services supplied. To <lb/>remedy this unintended effect, in 2005, the Government introduced an intermediate cap: for services <lb/>delivered between 102% and 113% of the cap, insurers paid only 33% of the cost. Insurers were therefore <lb/>given an incentive to spread their insurees across several hospitals. <lb/>Summary of tapering experiences <lb/>159. <lb/>In conclusion, the four case studies show that tapering payment is intended primarily to contain <lb/>the growth of hospital costs by imposing constraints on individual hospitals rather than the hospital sector <lb/>as a whole. Central authorities (ministries or independent agency) have a major say in setting the <lb/>parameters that govern tapering payments. In practice, where hospital payment is concerned, tapering is <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>53 <lb/></page>

			<body>essentially applied to the tariffs for the current year but is further adjusted by a process of reconciliation the <lb/>following year. <lb/>160. <lb/>Tapering payment is justified by the existence of economies of scale, even if the empirical <lb/>evidence for such economies in the hospital sector is not used in setting either the thresholds or rates of <lb/>tapering payment. This goes some way to explaining the wide range of rates in place in the four countries <lb/>studied. In some cases, the rates have been used for policy objectives. For example, in Maryland, at some <lb/>point, a tapering rate of 15% was decided upon to allow hospitals to increase their profitability so as to <lb/>encourage investment. <lb/>161. <lb/>Tapering payment does help to contain the growth of hospital costs, but there are very few <lb/>records of its impact on hospital volumes. Just one study in Maryland provided evidence of livelier growth <lb/>in activity between 2001 and 2008, a period when tapering was abolished. Given the moderate impact of <lb/>tapering payment on hospital activities, some countries are inclining towards a more rigorous system of <lb/>control over hospital activities such as a global budget (Czech Republic and Maryland). <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>54 <lb/></page>

			<body>Table 8: Summary <lb/>Czech Republic <lb/>Germany <lb/>Israel <lb/>Maryland <lb/>Hospital payment methods in 2013 or 2014 <lb/>Hospital <lb/>payment <lb/>method <lb/>DRGs since 2009 <lb/>(except in 2011). <lb/>DRGs since 2003 (80% <lb/>of hospital revenue). <lb/>Fee-for-service, <lb/>procedure-based <lb/>payments, per diem <lb/>payments. <lb/>Global budget and <lb/>DRGs (7% of hospitals <lb/>in 2014). <lb/>DRG-based <lb/>tariffs <lb/>Each hospital applies a <lb/>single DRG-based tariff <lb/>to all insurers. <lb/>Differences between <lb/>hospitals until 2014 <lb/>intended to smooth <lb/>the transition to DRG-<lb/>based payment and <lb/>tariffs were expected <lb/>to convergence. <lb/>A DRG catalogue based <lb/>on relative weights. <lb/>Base rate negotiated at <lb/>regional level, with <lb/>convergence towards a <lb/>single national base <lb/>rate. <lb/>Activity-based <lb/>payments based on <lb/>procedure-related <lb/>groups. <lb/> &quot; Target tariffs &quot; laid <lb/>down but they act only <lb/>to set a target global <lb/>budget based on an <lb/>approved care volume. <lb/>Hospitals are free to <lb/>adjust their bills <lb/>provided they remain <lb/>within the target <lb/>budget envelope. <lb/>Features of tapering payment in 2013-2014 <lb/>Date when <lb/>tapering was <lb/>introduced <lb/>2009, but a global <lb/>budget applied to <lb/>hospitals in 2011 and <lb/>2014. <lb/>1985 (before the <lb/>introduction of DRGs). <lb/>Second level of <lb/>tapering introduced in <lb/>2009. <lb/>1994 (introduction of <lb/>universal health <lb/>insurance), several <lb/>changes in parameters <lb/>since then. <lb/>1977, withdrawn <lb/>between 2001 and <lb/>2008, then <lb/>reintroduced. <lb/>Aims of <lb/>tapering <lb/>To prevent inflationary <lb/>effects during the shift <lb/>to DRG-based <lb/>payment. The <lb/>economic crisis and the <lb/>need to control growth <lb/>in expenditure led to <lb/>the system remaining <lb/>in use. <lb/>To contain hospital <lb/>spending growth and <lb/>volume increase; <lb/>justified by existence of <lb/>economies of scale in <lb/>hospital production. <lb/>To constrain growth in <lb/>the use of hospital <lb/>services and reduce <lb/>insurers&apos; expenditure <lb/>on services above a <lb/>given cap. <lb/>The rationale behind <lb/>the introduction of the <lb/>variable cost factor <lb/>(VCF) was to take into <lb/>account economies of <lb/>scale. <lb/>Areas where <lb/>tapering <lb/>applies <lb/>Almost all activities are <lb/>subject to tapering <lb/>payment. There may <lb/>be exceptions, but <lb/>these arise out of <lb/>bilateral agreements <lb/>between insurers and <lb/>hospitals, the details of <lb/>which are not readily <lb/>available. <lb/>All DRG-based <lb/>payments. Activities <lb/>excluded: transplants, <lb/>equipment-intensive <lb/>DRGs (2/3 of costs); <lb/>reduced tapering for <lb/>severely injured <lb/>All hospital activities. <lb/>All activities but <lb/>adjustments may be <lb/>made to allow for the <lb/>impact which new <lb/>activities will have. <lb/>Definition of <lb/>tapering <lb/>The Ministry of Health <lb/>draws up the formula <lb/>to be used to calculate <lb/>Principles laid down at <lb/>federal level (two <lb/>thresholds and two <lb/>Parameters (thresholds <lb/>and scales) laid down <lb/>by the Government for <lb/>Principles laid down by <lb/>the independent <lb/>government agency <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>55 <lb/></page>

			<body>Czech Republic <lb/>Germany <lb/>Israel <lb/>Maryland <lb/>parameters <lb/>the cap above which <lb/>tapering applies. <lb/>rates of tapering). <lb/> &quot; Negotiated &quot; activity <lb/>thresholds for each <lb/>hospital based on past <lb/>performance and <lb/>projected activity. <lb/>Tapering scales laid <lb/>down nationally (this <lb/>has changed over <lb/>time). <lb/>three years. <lb/>Hospitals and insurers <lb/>sign individual <lb/>contracts and <lb/>negotiate further <lb/>discounts and <lb/>adjustments in <lb/>tapering parameters in <lb/>90% of cases. <lb/>responsible for <lb/>managing hospital <lb/>charges (HSCRC, Health <lb/>Services Cost Review <lb/>Commission). <lb/>Tapering scale laid <lb/>down for all state <lb/>hospitals. <lb/>Threshold <lb/>above which <lb/>tapering <lb/>applies <lb/>The caps are the result <lb/>of a single method of <lb/>calculation laid down <lb/>by the Ministry which, <lb/>once applied to the <lb/>data from each <lb/>hospital, results in <lb/>different caps for each <lb/>insurer-hospital <lb/>pairing. The <lb/>parameters for the <lb/>calculation are an <lb/>increase in volumes of <lb/>cases treated, an <lb/>increase in severity per <lb/>case and an increase in <lb/>tariffs. <lb/>First threshold: activity <lb/>in the benchmark year <lb/>(all activity above this <lb/>threshold is paid at a <lb/>reduced tariff). <lb/>The second threshold is <lb/>the volume negotiated <lb/>between a hospital and <lb/>all relevant insurers. <lb/>An initial threshold <lb/>based on historical <lb/>trends and projections <lb/>for the number of <lb/>insured persons; above <lb/>this point, tapering <lb/>applies. <lb/>Three further <lb/>thresholds, each <lb/>defined as a <lb/>percentage of the first <lb/>threshold just the <lb/>tapering scale as <lb/>activity increases. <lb/>Any increase in activity <lb/>compared to t-1 is paid <lb/>only in line with the <lb/>scale of variable costs <lb/>(reduced charge). <lb/>Tapering <lb/>scales <lb/>50%. <lb/>First tapered scale: <lb/>25% in 2013. <lb/>Second tapered scale: <lb/>65%. <lb/>Scale 1 (applies <lb/>between 100% and <lb/>102% of the threshold): <lb/>30%. <lb/>Scale 2 (between 102% <lb/>and 113% of the <lb/>threshold): 67%. <lb/>Scale 3 (above 113% of <lb/>the threshold): 35%. <lb/>50% in the 1980s, <lb/>15% in the 1990s, <lb/>50% currently. <lb/>Benchmark <lb/>year and <lb/>adjustments <lb/>The trends accounted <lb/>for in the method of <lb/>calculating the cap are <lb/>calculated using year t <lb/>and year t-2. <lb/>Generally speaking, the <lb/>activity actually <lb/>performed in the <lb/>previous year acts as a <lb/>benchmark. In 2014, <lb/>the benchmark year is <lb/>2012. <lb/>In 2014, the <lb/>benchmark year was <lb/>2012 to avoid <lb/>incorporating a sharp <lb/>increase in activity that <lb/>occurred in 2013. <lb/>Generally speaking, the <lb/>activity actually <lb/>performed in the <lb/>previous year acts as a <lb/>benchmark with an <lb/>adjustment to avoid <lb/>paying for the fixed <lb/>costs associated with <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>56 <lb/></page>

			<body>Czech Republic <lb/>Germany <lb/>Israel <lb/>Maryland <lb/>an increase in activity <lb/>above the threshold. <lb/>Application <lb/>of tapering <lb/>in practice <lb/>Following year <lb/>(between April and <lb/>June). <lb/>Adjustment of tariffs in <lb/>the current year. <lb/>Adjustment of tariffs in <lb/>the current year. <lb/>Current year with the <lb/>option to make <lb/>corrections the <lb/>following year. <lb/>Hospital <lb/>protection <lb/>mechanisms <lb/>The hospital is <lb/>remunerated at a rate <lb/>of 20% for all activity <lb/>that is &quot; negotiated &quot; <lb/>but not performed. <lb/>Guaranteed income for <lb/>the hospital: full <lb/>remuneration for 95% <lb/>of the negotiated <lb/>activity, plus payment <lb/>of 30% of the price for <lb/>services not performed <lb/>in the range of 95%-<lb/>100% of the activity <lb/>cap &quot; &quot; negotiated &quot; . <lb/>Where activity is lower <lb/>than the revenue <lb/>authorised, the <lb/>hospital receives <lb/>payment for the share <lb/>of the fixed costs <lb/>incorporated in the <lb/>income that it should <lb/>have received in t. <lb/>Impact of tapering <lb/>Changes in <lb/>activity <lb/>The Ministry of Health <lb/>reported a slight fall in <lb/>case mix in 2012 but <lb/>did not link it to <lb/>tapering. <lb/>Lower rate of growth in <lb/>case mix since 2009, <lb/>but difficult to relate <lb/>this to the introduction <lb/>of the second level of <lb/>tapering. <lb/>Significant increase in <lb/>inpatient admissions, <lb/>outpatient <lb/>consultations and <lb/>operating costs <lb/>following the removal <lb/>of tapering between <lb/>2001 and 2008 <lb/>(Kalman, 2014). <lb/>Savings due <lb/>to tariff <lb/>reductions <lb/>Not known. <lb/>Expected savings in <lb/>2011-12 EUR 270-<lb/>350 million (0.5% of <lb/>hospital costs). <lb/>On average, 10% of all <lb/>payments to hospitals <lb/>if national parameters <lb/>are applied, plus 7% in <lb/>reductions secured <lb/>through negotiation. <lb/>Not known. <lb/>Impact on <lb/>waiting <lb/>times, <lb/>quality of <lb/>care <lb/>No evidence. <lb/>Unknown <lb/>No evidence. <lb/>No evidence. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>57 <lb/></page>

			<body>CONCLUSION <lb/>162. <lb/>In 2011, hospital care costs accounted for 29% of all health spending, on average, in OECD <lb/>countries and for 2.6% of gross domestic product (GDP). On average, hospital care costs in the OECD <lb/>countries continued to grow in 2010 and 2011, but at a markedly slower rate than in 2008 and 2009. Many <lb/>countries have taken measures to rein in public spending in this area: cutting the salaries paid to health <lb/>professionals, cutting staff numbers, reducing the fees paid to health care providers and increasing the <lb/>patient&apos;s out-of-pocket share, all in an attempt to ease the pressure on budgets (Morgan and Astolfi, 2013). <lb/>163. <lb/>In most OECD countries, spending on hospitals is funded mainly by the public sector. Whilst <lb/>health systems vary across the OECD countries, there are similarities in the way hospital costs are <lb/>financed. On average, across OECD countries, 88% of these costs were funded by the public sector in <lb/>2011. One exception is the United States where private insurers meet 36% of hospital costs. This is due to <lb/>the fact that 53% of the US population are covered by private insurance. In most other OECD countries, <lb/>private insurance has a much more limited role providing only complementary or supplementary insurance <lb/>for their population. As a result, private insurers only finance about 5% of hospital spending across OECD <lb/>countries. Patients also contribute to the costs of hospital care, by 6% on average across the OECD. <lb/>164. <lb/>Whereas global budgets are the predominant mode of payment for hospital services in tax-funded <lb/>national health systems, remuneration through DRGs is the main mode to pay hospital in countries with <lb/>social health insurance. Two-third of countries with a health insurance system have opted for DRG-based <lb/>payment or payment per case to public hospitals as the main mode of payment (14 out of 20) and three <lb/>others have chosen fee-for-service payment, which also ties the hospital&apos;s payment to the activity it <lb/>performs. 29 DRG-based hospital payment was introduced in OECD countries with different objectives, <lb/>such as: increase efficiency in the use of resources in hospitals, contain hospital costs, increase <lb/>transparency, reduce waiting times, better allocate resources between hospitals and/or improve the quality <lb/>of care. <lb/>165. <lb/>To control the inflationary effects of DRG-based payment, some OECD countries have <lb/>introduced a tapering scale of rates for DRG-based payment above a defined volume of production. The <lb/>main reason given to justify this mechanism is that economies of scale can be achieved within the hospital <lb/>production system. Whilst the empirical evidence for such economies in the hospital sector is unclear, it is <lb/>generally recognised in these countries that, above a given level of production, fixed costs have been paid <lb/>for and hospitals can only be paid for variable costs. Tapering payments have been introduced in six <lb/>OECD countries: Germany, USA (State of Maryland), the Czech Republic, Israel, Australia and Hungary. <lb/>Detailed case studies have been conducted on four of these – Germany, Maryland, the Czech Republic and <lb/>Israel – to identify the main economic, institutional and technical issues entailed in introducing a tapering <lb/>scale mechanism. <lb/>166. <lb/>The four case studies conclude that tapering payment is intended primarily to contain the growth <lb/>of hospital costs and is justified by the existence of economies of scale. But the circumstances surrounding <lb/>its introduction vary. In Maryland and initially in Germany, the main motivation is to capture the financial <lb/>29 <lb/>Source: http://www.oecd.org/els/health-systems/characteristics.htm. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>58 <lb/></page>

			<body>gains of the economies of scale realised. In Israel and the Czech Republic, it was introduced in response to <lb/>the fear that activity volumes might increase, as a result of generalised health insurance coverage (in Israel) <lb/>or of the introduction of DRG-based payment (in the Czech Republic). This is also true for Germany, <lb/>where the re-introduction of the second tapering mechanism in 2013 was intended to rein in activity <lb/>growth. <lb/>167. <lb/>The levels of hospital activity above which tapering scale rates apply are set on the basis of data <lb/>for past years and projections of how demand will develop. In Germany and the State of Maryland, the <lb/>threshold at which tapering begins is the level of activity of the reference year (usually the previous year); <lb/>all activities above this level are paid at a reduced tariff. In the Czech Republic, a single annual formula <lb/>determines the threshold above which tapering applies to each hospital/insurance fund contract, set on the <lb/>basis of the change in activity between t-2 and t. In Israel, the thresholds for tapering are agreed every year <lb/>between each insurer and hospital. Thresholds are set in terms of the change in activity volume (case mix) <lb/>in most of the countries studied. Israel alone sets them on the basis of the hospital&apos;s gross revenue. <lb/>168. <lb/>Central authorities (ministries or independent agency) have a major role in setting tapering scales, <lb/>or reductions on the full tariff, whether these are agreed by negotiation or imposed unilaterally. In 2009 <lb/>and 2012, in Germany, the scale was negotiated in each Land by the regional hospital and insurance fund <lb/>associations; the scale was decreed by federal law for the years 2013 and 2014 and is applicable <lb/>nationwide. Scales are set by the Ministry of Health in the Czech Republic and by an independent <lb/>government agency in the State of Maryland. In Israel, tapering scales are set by the health and finance <lb/>ministries, but only 10% of contracts signed between insurers and hospitals apply them as they stand. For <lb/>90% of contracts, rates and thresholds are renegotiated by the parties to the contract. <lb/>169. <lb/>Tapering scales vary considerably from one country to another, and two countries apply different <lb/>rates for different bands of activity. Tapering scale rates, supposedly reflecting the proportion of fixed <lb/>costs in total hospital costs, stood between 25% and 67% in 2013 in the countries analysed. These rates <lb/>varied over time as a result of negotiation or to meet a number of policy objectives (encouraging <lb/>investment, for example). Currently, Maryland and the Czech Republic apply a reduction of 50%. In <lb/>Germany, a starting rate of 25% is applied to any activity above that of the reference year, and a second <lb/>rate of 65% applies to activity beyond a &quot; negotiated &quot; activity threshold. Since this negotiation is, in effect, <lb/>a projection of activity for the current year which is agreed by the contracting parties, the second threshold <lb/>is only rarely applied. In Israel, there are three set rates corresponding to three different activity thresholds <lb/>(30%, 67% and 35%). The second rate (67%) seeks to encourage insurers to spread their insurees over all <lb/>hospitals rather than concentrating all activity on just one hospital, to maximise the benefits of tapering <lb/>payment. All the countries acknowledge the existence of economies of scale in hospital production, but in <lb/>each country there is no national or scientific study justifying the rate applied or negotiated. The tapering <lb/>mechanism in Maryland is the most coherent in terms of economies of scale, because hospitals are paid the <lb/>fixed costs of every activity that is planned but not performed. In the most usual situation where the <lb/>hospital exceeds its activity ceiling, the hospital is paid only for its variable costs, and reassessment of the <lb/>ceiling the following year disregards this excess activity above the ceiling. <lb/>170. <lb/>Tapering payment is applied uniformly to all hospital activities, but Germany and Maryland <lb/>make adjustments to allow for the impact of new activities. These adjustments are made in two ways. <lb/>Germany excludes certain treatments or services from tapering payment, for example, treatments where <lb/>equipment costs are more than two-thirds of the total cost of the procedure, or new activities entailed in <lb/>setting up a new service or a new operating theatre. In Maryland, hospitals are able to negotiate with the <lb/>government agency responsible for hospital charges and agree increases in the activity ceiling above which <lb/>tapering payment will apply after new activities are created. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>59 <lb/></page>

			<body>171. <lb/>Tapering is essentially applied to the remuneration rates for the current year but is further <lb/>adjusted by a process of reconciliation the following year. In Germany, Maryland and Israel, the estimated <lb/>effect of tapering is spread over all DRG tariffs for the current year, which are set annually (Germany) or <lb/>adjusted monthly (Israel). In Germany, an a posteriori reconciliation is carried out to take account of any <lb/>mismatch between activities planned and activities actually performed. Hospitals in Maryland have a <lb/>software which allows them to factor tapering payment and authorised income into their invoiced prices. In <lb/>the Czech Republic, by contrast, the amount of tapering is calculated ex post, and it takes the form of <lb/>reductions on future activities which the hospital invoices to each insurer. <lb/>172. <lb/>The impact of tapering payment on hospital activity is unclear. It does, in principle, help to <lb/>contain the growth of hospital costs. In Germany, the tapering scale&apos;s starting band was assumed to <lb/>generate savings of 350 Mio EUR and 270 Mio EUR in 2011 and 2012 respectively (around 0.5% of total <lb/>spending) but it is important to note that annual case-mix increases seemed to have slowed down with the <lb/>introduction of the tapering mechanism. In Israel, the &quot; theoretical &quot; saving is put at 10% of total payments <lb/>to hospitals, but in fact higher savings are negotiated between insurers and hospitals. There is, however, <lb/>only one study that demonstrates the impact of this mechanism on hospital volumes. Maryland saw a more <lb/>dynamic pace of growth in activity from 2001 to 2008, a period when tapering was abolished. At the same <lb/>time, tapering seems to have had an effect on the organisation of hospitals in Maryland where hospitals <lb/>developed management tools which allowed them to monitor the activity of health practitioners (who are <lb/>independent). The introduction of tapering scale does not seem to reduce access of patients to hospitals <lb/>services. No stakeholder interviewed for this project (hospitals and insurers) believed that hospitals turn <lb/>away patients or defer certain treatments in order to avoid being paid at a lower tariff. <lb/>173. <lb/>Given the moderate impact of tapering payment on hospital activities, some of the countries <lb/>studied are inclined to introduce more rigorous systems of control. The Czech Republic has reverted to a <lb/>global budget for 2014 in order to have tighter control over hospital spending. In Maryland, the majority of <lb/>hospitals will be paid through global budget in 2014, in an attempt to keep growth in total hospital <lb/>spending in line with growth in the State&apos;s wealth. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>60 <lb/></page>

			<listBibl>REFERENCES <lb/>Albreht, T. et al. (2009), &quot; Slovenia: Health System Review &quot; , Health Systems in Transition, <lb/>Volume 11(3), pp. 1–168. <lb/>Augurzky, B et al. (2012), Mengenentwicklung und Mengensteuerung stationärer Leistungen: <lb/>Endbericht – Mai 2012. Forschungsbericht im Auftrag des GKV-Spitzenverbandes, RWI <lb/>Projektberichte, http://nbn-resolving.de/urn:nbn:de:hbz:061:3-20199 <lb/>Barros, P. and R. Gonçalves (2009), &quot; Economies of scale and scope in the provision of diagnostic <lb/>techniques and therapeutic services in Portuguese hospitals &quot; , Applied Economics, Taylor &amp; <lb/>Francis Journals, Volume 45(4), pp. 415–433 (working paper). <lb/>Bellanger, M. et al. (2008), &quot; What can we learn from a cross-country comparison of the costs of <lb/>child delivery? &quot; , Health Economics, Volume 17, pp. 47–57. <lb/>Bowers, T. (2014), &quot; Hot issues in Israel&apos;s healthcare system &quot; , Policy Brief, Taub Center for <lb/>Social Policy Studies. <lb/>Bryndová, L. et al. (2009), &quot; Czech Republic: Health System Review &quot; , Health Systems in <lb/>Transition, Volume 11(1), pp. 1–122. <lb/>Bundestagsdrucksache 17/3360, Entwurf eines Gesetzes zur nachhaltigen und sozial <lb/>ausgewogenen Finanzierung der Gesetzlichen Krankenversicherung (GKV-<lb/>Finanzierungsgesetz – GKV-FinG), Deutscher Bundestag, Berlin. <lb/>Bundestagsdrucksache 17/13947, Beschlussempfehlung und Bericht des Ausschusses für <lb/>Gesundheit (14. Ausschuss), Deutscher Bundestag, Berlin. <lb/>Busse et al. (2007), &quot;International comparison of costs: an exploration of within-and between-counrty <lb/>variations for ten healthcare services in nine EU member states&quot;, Final Report, Center for Health <lb/>economics <lb/>and <lb/>Berlin <lb/>University <lb/>of <lb/>Technology, <lb/>http://www.ehma.org/files/WP10%20REPORT_31_Jan-07_revised.pdf <lb/>Busse, R. et al. (2008), &quot; Variability in healthcare treatment costs amongst nine EU countries – <lb/>results from the HealthBASKET project &quot; , Health Economics, Volume 17, pp. 1–8. <lb/>Busse, R. et al. (2011), &quot; Diagnosis-Related Groups in Europe: Moving towards transparency, <lb/>efficiency and quality in hospitals &quot; , European Observatory on Health Systems and Policies <lb/>Series. <lb/>Busse, R. et al. (2011), &quot; Germany: Understanding G-DRGs &quot; in Diagnosis-Related Groups in <lb/>Europe: Moving towards transparency, efficiency and quality, European Observatory on <lb/>Health Systems and Policies Series. <lb/></listBibl>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>61 <lb/></page>

			<listBibl>Center for Medicare and Medicaid Innovation (2013), &quot; Maryland&apos;s All-Payer Model &quot; , submitted <lb/>by the Maryland Department of Health and Mental Hygiene. <lb/>Carey, K. (2000), &quot; A panel data design for estimation of hospital cost functions &quot; , The Review of <lb/>Economics and Statistics, Volume 79, Issue 3, pp. 443–453. <lb/>Cohen, J.P. et al. (2008), &quot; Agglomeration and Cost Economies for Washington State Hospital <lb/>Services &quot; , Regional Science and Urban Economics, Volume 38. <lb/>Cohen, J.P. et al. (2010), &quot; Health care reform and Connecticut&apos;s non-profit hospitals &quot; , Journal of <lb/>Health Care Finance, Volume 37, pp. 1–7. <lb/>Connor, R. et al. (1998), &quot; The Effects of Market Concentration and Horizontal Mergers on <lb/>Hospital Costs and Prices &quot; , International Journal of the Economics of Business, Volume 5, <lb/>Issue 2, pp. 159–180. <lb/>Cowing, T.G. and A.G. Holtmann (1983), &quot; Multiproduct Short-Run Hospital Cost Functions: <lb/>Empirical Evidence and Policy Implications from Cross-Section Data &quot; , Southern Economic <lb/>Journal, Volume 49, No. 3 (Jan., 1983), pp. 637–653. <lb/>Czach, K. et al. (2011), &quot; Poland: The Jednorodne Grupy Pacjentów – Polish experiences with <lb/>DRGs &quot; , in Diagnosis-Related Groups in Europe: Moving towards transparency, efficiency <lb/>and quality in hospitals, European Observatory on Health Systems and Policies Series <lb/>(2011). <lb/>Deutsches Krankenhausinstitut (2010), &quot; Krankenhaus Barometer – Umfrage 2010 &quot; , <lb/>http://www.dki.de/sites/default/files/downloads/krankenhaus-barometer-2010.pdf <lb/>Ellis, R. P. and T.G. McGuire (1993), &quot; Supply-Side and Demand-Side Cost Sharing in Health <lb/>Care &quot; , Journal of Economic Perspectives, Volume 7(4), pp. 135–151. <lb/>Endrei, D. et al. (2013), &quot; The effect of performance-volume limit on the DRG based acute care <lb/>hospital <lb/>financing <lb/>in <lb/>Hungary &quot; , <lb/>Health <lb/>Policy. <lb/>http://dx.doi.org/10.1016/j.healthpol.2013.12.005. <lb/>Epstein, D., et al. (2008), &quot; The hospital costs of care for stroke in nine European countries &quot; , <lb/>Health Economics, Volume 17, pp. 21–31. <lb/>Euro Observer (2010), Volume 10, No 3. <lb/>Gaal, P. et al. (2006), &quot; Cost accounting methodologies in price setting of acute inpatient services <lb/>in Hungary &quot; , Health Care Management Science (2006) 9: pp. 243–250. <lb/>Healy, J., E. Sharman and B. Lokuge (2006), &quot; Australia: Health System Review &quot; , Health Systems <lb/>in Transition, Volume 8(5), pp. 1–158. <lb/>Heimig, F., CEO InEK GmbH, &quot; Implementation and development of G-DRG in Germany &quot; , <lb/>http://www.nrc.cz/system/files/2011/10/heimig_implementation_and_development_g_drg_i <lb/>n_ger_15093.pdf. <lb/></listBibl>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>62 <lb/></page>

			<listBibl>Ho, V. and L.A. Petersen (2007), &quot; Estimating cost savings from regionalizing cardiac procedures <lb/>using hospital discharge data &quot; , Cost Effectiveness and Resource Allocation, Volume 5, <lb/>Issue 7. <lb/>Kalman, N.S. (2014), &quot; Removing a constraint on hospital utilization: Implications for cost <lb/>growth &quot; , Am J Manag Care, vol. 20(6). <lb/>KCE (2013), &quot; A comparative analysis of hospital care payments in five countries &quot; , KCE Reports <lb/>207. <lb/>Kim, D. et al. (2011), &quot; Medicare Payment Reform and Hospital Costs: Evidence from the <lb/>Prospective Payment System and the Treatment of Cardiac Disease &quot; , Working Paper. <lb/>Kinkorová, J. and O. Topolčan (2012), &quot; Overview of healthcare system in the Czech Republic &quot; , <lb/>The EPMA Journal, Volume 3(4). <lb/>Kobel, C. et al. (2011), &quot; DRG systems and similar patient classification systems in Europe &quot; , in <lb/>Diagnosis-Related Groups in Europe: Moving towards transparency, efficiency and quality <lb/>in hospitals, European Observatory on Health Systems and Policies Series. <lb/>Kristensen, T. et al. (2012), &quot; Economies of scale and scope in the Danish hospital sector prior to <lb/>radical restructuring plans &quot; , Health Policy, Volume 106, Issue 2, pp. 120–126. <lb/>Kumar, A. and M. Schoenstein (2013), &quot; Managing Hospital Volumes: Germany and Experiences <lb/>from OECD Countries &quot; , OECD Health Working Papers, No. 64, OECD Publishing. <lb/>Kutzin, J. et al. (2010), &quot; Implementing health financing reform: Lessons from countries in <lb/>transition &quot; , World Health Organization. <lb/>Li, T. and R. Rosenman (2001), &quot; Estimating hospital costs with a generalized Leontief function &quot; , <lb/>Health Economics, Volume 10. <lb/>Marini, G. et al. (2009), &quot; Economies of scale and scope in the English hospital sector &quot; , <lb/>Discussion Paper 2009/05. <lb/>Maryland <lb/>Hospital <lb/>Association <lb/>(2014), <lb/> &quot; Policies <lb/>for <lb/>Controlling <lb/>Volume &quot; , <lb/>http://www.hscrc.state.md.us/documents/md-maphs/wp-sub/MHA-paper-on-volume-and-<lb/>PAU-revised-01-10-2014.pdf. <lb/>Menke, T.J. (1997), &quot; The effect of chain membership on hospital costs &quot; Health Services <lb/>Research, Volume 32(2), pp. 177–196. <lb/>Morgan, D. and R. Astolfi (2013), &quot; Health Spending Growth at Zero: Which Countries, Which <lb/>Sectors Are Most Affected? &quot; , OECD Health Working Papers, No. 60, OECD Publishing. <lb/></listBibl>

			<note place="footnote">Müller, P. et al. (2013), &quot; Understanding the German Health Care System &quot; , booklet published by <lb/>the <lb/>Mannheim <lb/>Institute <lb/>of <lb/>Public <lb/>Health <lb/>(MIPH) <lb/>http://www.goinginternational.eu/newsletter/2013/nl_03/SpecialDE_EN_Understanding_the <lb/>_German.pdf. <lb/></note>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>63 <lb/></page>

			<listBibl>Murray, R. (2009), &quot; Setting Hospital Rates To Control Costs And Boost Quality: The Maryland <lb/>Experience &quot; , Health Affairs, 28, No. 5 (2009): pp. 1395-1405. <lb/>National Center for Health Statistics (2013), &quot; Health, United States, 2012: With Special Feature on <lb/>Emergency Care &quot; , Hyattsville, MD. <lb/>OECD (2012), &quot; OECD Reviews of Health Care Quality: Israel 2012 – Raising Standards &quot; , OECD <lb/>Publishing. <lb/>OECD HSC (2012), Health System Characteristics Survey 2012. <lb/>OECD (2013), &quot; Health at a Glance &quot; , OECD Publishing. <lb/>Or, Z. and M. Bellanger (2011), &quot; France: Implementing homogeneous patient groups in a mixed market &quot; <lb/>in Diagnosis-Related Groups in Europe: Moving towards transparency, efficiency and quality in <lb/>hospitals, European Observatory on Health Systems and Policies Series. <lb/>Quentin, W. et al. (2011), &quot; Understanding DRGs and DRG-based hospital payment in Europe &quot; , in <lb/>Diagnosis-Related Groups in Europe: Moving towards transparency, efficiency and quality in <lb/>hospitals, European Observatory on Health Systems and Policies Series. <lb/>Quentin, W. et al. (2013), &quot; Hospital Payment Based On Diagnosis-Related Groups Differs In Europe And <lb/>Holds Lessons For The United States &quot; , Health Affairs, Volume 32, No. 4, pp. 713–723. <lb/>Rice, T. et al. (2013) &quot; United States of America: Health System Review &quot; , Health Systems in Transition, <lb/>Volume 15(3), pp. 1– 431. <lb/>Roll K, Stargardt T and J Schreyögg (2012), The effect of type of insurance and income on waiting time in <lb/>outpatient care, in: Geneva Papers on Risk and Insurance, Issues and Practice <lb/>Rosen, B and S. Merkur (2009), &quot; Israel: Health System Review &quot; , Health Systems in Transition, <lb/>Volume 11(2), pp. 1–226. <lb/>Schäfer, W. et al. (2010), &quot; The Netherlands: Health System Review &quot; , Health Systems in Transition, <lb/>Volume 12(1), pp. 1–229. <lb/>Sagan, A. et al. (2011) &quot; Poland: Health System Review &quot; , Health Systems in Transition, Volume 13(8), <lb/>pp. 1–193. <lb/>Schreyögg, J. et al. (2006), &quot; Methods to determine reimbursement rates for diagnosis related groups <lb/>(DRG): A comparison of nine European countries &quot; , Health Care Management Science, Volume 9, <lb/>pp. 215–223. <lb/>Schreyögg, J. (2008), &quot; A micro-costing approach to estimating hospital costs for appendectomy in a cross-<lb/>European context &quot; . Health Economics, Volume 17, pp. 59–69. <lb/>Schreyögg J et al. (2014), Forschungsauftrag zur Mengenentwicklung nach Paragraph 17b Abs. 2 KHG <lb/>download under: http://www.dkgev.de/media/file/17192.2014-07-10_Anlage_Forschungsbericht-<lb/>zur-Mengenentwicklung_FIN.pdf <lb/>Schut, E., S. Sorbe and J. Høj (2013), &quot; Health Care Reform and Long-Term Care in the Netherlands &quot; , <lb/>OECD Economics Department Working Papers, No. 1010, OECD Publishing. <lb/></listBibl>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>64 <lb/></page>

			<listBibl>Siciliani, L., M. Borowitz and V. Moran (2013), &quot; Waiting Time Policies in the Health Sector: What <lb/>Works? &quot; , OECD Health Policy Studies, OECD Publishing, <lb/>http://dx.doi.org/10.1787/9789264179080-en. <lb/>Smet, M. (2007), &quot; Measuring performance in the presence of stochastic demand for hospital services: an <lb/>analysis of Belgian general care hospitals &quot; , Journal of Productivity Analysis, Volume 27, pp. 13–29. <lb/>Smith, J.C. and C. Medalia (2014), Health Insurance in the United States: 2013, Current Population <lb/>Reports, U.S. Department of Commerce, Economics and Statistics Administration, U.S. Census <lb/>Bureau <lb/>Street, A. et al., (2007), &quot; Introducing Activity-Based Financing: a Review of Experience in Australia, <lb/>Denmark, Norway and Sweden &quot; , CHE Research Paper 30, Centre for Health Economics, University <lb/>of York. <lb/>Tiemann, O. (2008), &quot; Variations in hospitalisation costs for acute myocardial infarction – a comparison <lb/>across Europe &quot; , Health Economics, Volume 17, pp. 33–45. <lb/>Tuschen KH, Braun T, Rau F (2005), &quot; Erlösausgleich im Krankenhausbereich: Eine Orientierungshilfe &quot; <lb/>in Das Krankenhaus 11/2005. Deutsche Krankenhausgesellschaft, Verlag W.Kohlhammer GmbH, <lb/>Stuttgart. <lb/>VZP (2008), http://www.vzp.cz/en/index.php. <lb/>Vita, M.G. (1990), &quot; Exploring hospital production relationships with flexible functional forms &quot; , Journal of <lb/>Health Economics, pp. 1-21. <lb/>Wang, J. et al. (2006), &quot; Relative Efficiency, Scale Effect, and Scope Effect of Public Hospitals: Evidence <lb/>from Australia &quot; , IZA DP No. 2520. <lb/></listBibl>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>65 <lb/></page>

			<body>ANNEX 1: DETAILED DESCRIPTION OF THE FEATURES OF DRG-BASED PAYMENT <lb/>SYSTEMS IN OECD COUNTRIES <lb/>174. <lb/>DRG systems exist in nearly all OECD countries but they can serve different purposes. Whereas <lb/>they are used as method to pay for hospital activity in a number of countries they are used as a patient <lb/>classification system to define hospital budgets in others (Geissler et al., 2011). For a more detailed <lb/>appraisal of the characteristics of DRG-based payment in the OECD countries, the following parameters <lb/>were analysed for each country: date when DRG-based payment was introduced, classification system <lb/>used, number of DRG hospital groups, and intervals at which the payment system is revised (Table A.1). <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>66 <lb/></page>

			<body>Table A.1: History and main characteristics of hospital stay classification systems introduced in selected <lb/>OECD countries <lb/>Date <lb/>introduced <lb/>Classification <lb/>system <lb/>Number of groups <lb/>Revision <lb/>Germany <lb/>2003 <lb/>G-DRG 2012 <lb/>1 193 <lb/>Annually <lb/>Austria <lb/>1997 <lb/>Katalog <lb/>medizinischer <lb/>Einzelleistungen <lb/>(MEL) for <lb/>procedures <lb/>1 004 <lb/>Marginal adjustment <lb/>annually and full revision <lb/>every 7 years <lb/>USA (Medicare) <lb/>1983 <lb/>MSDRGs <lb/>~2 400 <lb/>Annually <lb/>France <lb/>2005 <lb/>GHM <lb/>~2 500 <lb/>Annually <lb/>Netherlands <lb/>2005 <lb/>DBC <lb/>~30 000 <lb/>Sporadically <lb/>Czech Rep. <lb/>2009 <lb/>Adjusted IR DRG <lb/>1 046 <lb/>Annually <lb/>Slovenia <lb/>2003 <lb/>ICD-10-AM (AR-<lb/>DRG V 4.2) <lb/>653 <lb/>Minor amendments <lb/>annually <lb/>Switzerland <lb/>2012 <lb/>SwissDRG 1.0 <lb/>991 <lb/>Annually <lb/>Australia <lb/>2003 and <lb/>nationwide as <lb/>of 2012 <lb/>AR-DRG <lb/>Classification <lb/>(Version 6.0) <lb/>698 <lb/>Every one to 2 years <lb/>Chile <lb/>2003 <lb/>Valued benefit <lb/>program <lb/>n.a. <lb/>Annually <lb/>Denmark <lb/>2004 <lb/>DKDRG 2012 <lb/>717 <lb/>Annually <lb/>Finland <lb/>1997 <lb/>NordDRG <lb/>500 inpatient, ~900 <lb/>including outpatients <lb/>Annually <lb/>United Kingdom 2003 partially <lb/>HRG v4 <lb/>~1 200 <lb/>Annually <lb/>Italy <lb/>1995 <lb/>DRG 24 v <lb/>538 <lb/>Every 3 years <lb/>Norway <lb/>1997 <lb/>NordDRG <lb/>870 <lb/>Annually <lb/>Portugal <lb/>1984 <lb/>AP-DRG v21 <lb/>669 <lb/>Sporadically <lb/>Sweden <lb/>1995 <lb/>NordDRG <lb/>983 (in and outpatient, <lb/>day cases) <lb/>Annually <lb/>Note: The Netherlands is currently reforming its payment system and associated classification (KCE, 2013). <lb/>Source: OECD Health System Characteristics Survey, 2012. <lb/>175. <lb/>The USA was the first country to introduce a DRG-based classification for its hospitals as part of <lb/>its Medicare programme (for patients aged 65 and over). Use of this patient classification system grew and <lb/>accelerated in OECD countries during the 2000s as information technology became more sophisticated. <lb/>Thirteen OECD countries adopted this system during the 2000s out of the 21 which now use it and for <lb/>which figures are available. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>67 <lb/></page>

			<body>176. <lb/>Three types of OECD countries can be distinguished by the way in which they went about <lb/>adopting DRG-based payment systems (Busse et al., 2011). Some countries, like Spain, Portugal and <lb/>Ireland, imported a classification system from abroad. Spain and Portugal, for example, adopted the All-<lb/>Patient DRG system (AP-DRG) developed in the USA. Other countries such as Australia imported the US <lb/>system and used it as a starting point for developing their own DRG systems. Thus, Australia created the <lb/>Australian National DRG (AN-DRG) which served as a starting point for the German DRG (G-DRG) <lb/>system. Other countries opted to devise their patient classification systems as a collaborative effort. The <lb/>Nordic countries, for example, created a common NordDRG system that is further adjustable to country-<lb/>specific conditions. The United Kingdom, Austria, the Netherlands and France decided to develop their <lb/>own systems. <lb/>177. <lb/>Within classifications, the number of homogeneous patient groups differ. There are 526 groups in <lb/>the patient classification system used by Poland, but there are about 2 500 groups in the French system. <lb/>That said, the difference between group numbers in certain countries does not de facto indicate a difference <lb/>in approach. In Australia, for example, there are some 700 groups as against about 2 500 in France. This <lb/>difference simply reflects a different way of dealing with the severity of the cases treated. In France, <lb/>severity level -measured by the patient&apos;s age or the existence of comorbidities-is taken into account in a <lb/>separate group. In Australia, severity, measured approximately in terms of length of stay, is reflected by <lb/>the application of different tariffs within one and the same group. Thus, the number of groups is lower in <lb/>Australia than in France, but this does not mean that Australia covers fewer severe conditions than France. <lb/>178. <lb/>Regarding the scope of DRG-based payment, most OECD countries do not include training or <lb/>teaching activities in the calculation of DRG-based payments (Table A.2). Hospitals are usually <lb/>remunerated for these activities out of a global envelope. When DRG-based payment is used in hospitals of <lb/>different legal status, the same rule applies to all hospitals, except in the USA&apos;s Medicare programme <lb/>where teaching and training activities are not taken into account when calculating DRG-based payment in <lb/>private not-for-profit hospitals but are taken into account in private for-profit hospitals and public <lb/>hospitals. <lb/>179. <lb/>A significant proportion of DRG-based payments include capital costs in the calculation of tariffs <lb/>(Netherlands, France, Switzerland, USA, Denmark, Finland, Italy, United Kingdom) irrespective of <lb/>whether of DRGs paid to public or private hospitals. <lb/>180. <lb/>Most OECD countries which use DRG-based payment include doctors&apos; fees in their calculation <lb/>of cost-per-case tariffs (Table A.3). In some countries they might be excluded depending on the <lb/>circumstances. In France, payments to doctors are included in the DRG-tariff calculated for public <lb/>hospitals but not in those billed to private for-profit hospitals where fees are invoiced separately. Germany <lb/>does not take into account the fees of specialists who are not hospital-based but are authorised to operate in <lb/>a hospital setting in the DRGs billed by hospitals. In this case, the hospital is paid for the patient&apos;s care <lb/>episode and the specialist can invoice the patient for the fees for his treatment. <lb/>181. <lb/>In most OECD countries, DRG-based payment also stretches to cover day care costs. When it <lb/>comes to expensive drugs only eight of the 23 countries for which figures are available and which use <lb/>DRG-based payment as the main method of remunerating hospitals include them all in their DRG tariffs. <lb/>In the other countries, there are additional payments either for all expensive drugs or for specific drugs. In <lb/>Italy, for example, most of the regions authorise additional payments for anti-cancer drugs. Likewise, in <lb/>Sweden, some regions pay for some expensive drugs separately. The findings are similar for expensive <lb/>medical devices. <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>68 <lb/></page>

			<body>Table A.2: Inclusion of capital costs and training and teaching activities in DRG-based payments in the OECD countries <lb/>Source: OECD Health System Characteristics Survey 2012. <lb/>Public hospital <lb/>Not-for-profit private hospital <lb/>For-profit private hospital <lb/>Public hospital <lb/>Not-for-profit <lb/>private hospital <lb/>For-profit <lb/>private <lb/>hospital <lb/>Public <lb/>hospital <lb/>Not-for-<lb/>profit <lb/>private <lb/>hospital <lb/>For-profit <lb/>private hospital <lb/>Austria <lb/>DRG-based payment <lb/>DRG-based payment <lb/>DRG-based payment <lb/>No <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Chile <lb/>DRG-based payment <lb/>DRG-based payment <lb/>Line-item remuneration <lb/>No <lb/>No <lb/>No <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Czech <lb/>Republic <lb/>Block budget <lb/>Block budget <lb/>Block budget <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Estonia <lb/>DRG-based payment <lb/>n.a. <lb/>n.a. <lb/>Yes <lb/>--<lb/>--<lb/>Yes <lb/>--<lb/>--<lb/>France <lb/>DRG-based payment <lb/>DRG-based payment <lb/>DRG-based payment <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Germany <lb/>DRG-based payment <lb/>DRG-based payment <lb/>DRG-based payment <lb/>No <lb/>No <lb/>No <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Greece <lb/>DRG-based payment <lb/>DRG-based payment <lb/>Fee-for-service payment <lb/>No <lb/>No <lb/>Yes <lb/>No <lb/>No <lb/>No <lb/>Hungary <lb/>DRG-based payment <lb/>DRG-based payment <lb/>Fee-for-service payment <lb/>No <lb/>No <lb/>Yes <lb/>No <lb/>No <lb/>No <lb/>Israel <lb/>Fee-for-service payment <lb/>Fee-for-service payment <lb/>Fee-for-service payment <lb/>No <lb/>No <lb/>No <lb/>No <lb/>No <lb/>No <lb/>Korea <lb/>Fee-for-service payment <lb/>Fee-for-service payment <lb/>n.a. <lb/>Yes <lb/>Yes <lb/>--<lb/>No <lb/>No <lb/>--<lb/>Luxembourg <lb/>Block budget <lb/>Block budget <lb/>n.a. <lb/>No <lb/>No <lb/>--<lb/>Yes <lb/>Yes <lb/>--<lb/>Netherlands <lb/>DRG-based payment <lb/>DRG-based payment <lb/>n.a. <lb/>Yes <lb/>Yes <lb/>--<lb/>Yes <lb/>Yes <lb/>--<lb/>Poland <lb/>DRG-based payment <lb/>DRG-based payment <lb/>DRG-based payment <lb/>No <lb/>No <lb/>No <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Slovenia <lb/>DRG-based payment <lb/>DRG-based payment <lb/>DRG-based payment <lb/>Yes <lb/>Yes <lb/>--<lb/>Yes <lb/>Yes <lb/>--<lb/>Switzerland <lb/>DRG-based payment <lb/>DRG-based payment <lb/>DRG-based payment <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Yes <lb/>USA <lb/>DRG-based payment <lb/>DRG-based payment <lb/>Fee-for-service payment <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Yes <lb/>No <lb/>Yes <lb/>Australia <lb/>DRG-based payment <lb/>Fee-for-service payment <lb/>Fee-for-service payment <lb/>No <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Denmark <lb/>Block budget <lb/>n.a. <lb/>DRG-based payment <lb/>Yes <lb/>--<lb/>Yes <lb/>No <lb/>--<lb/>No <lb/>Finland <lb/>DRG-based payment <lb/>Yes <lb/>--<lb/>--<lb/>Yes <lb/>--<lb/>--<lb/>Italy <lb/>Block budget <lb/>DRG-based payment <lb/>DRG-based payment <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Yes <lb/>No <lb/>Norway <lb/>Block budget <lb/>Block budget <lb/>DRG-based payment <lb/>Yes <lb/>Yes <lb/>No <lb/>No <lb/>No <lb/>No <lb/>United <lb/>Kingdom <lb/>DRG-based payment <lb/>Fee-for-service payment <lb/>Fee-for-service payment <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Hospital payments <lb/>Capital costs taken into account <lb/>Teaching and training taken into <lb/>account separately <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>69 <lb/></page>

			<body>Table A.3: Scope of DRG-based payment for certain health services in the OECD countries <lb/>Source: OECD Health System Characteristics Survey 2012. <lb/>Public hospital <lb/>Not-for-profit private hospital <lb/>For-profit private hospital <lb/>Austria <lb/>DRG-based payment <lb/>DRG-based payment <lb/>DRG-based payment <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Yes <lb/>Belgium <lb/>Block budget <lb/>Block budget <lb/>n.a. <lb/>No <lb/>No <lb/>No <lb/>No <lb/>Chile <lb/>DRG-based payment <lb/>DRG-based payment <lb/>Line-item remuneration <lb/>No <lb/>In some cases <lb/>Yes <lb/>In some cases <lb/>Czech Republic <lb/>Block budget <lb/>Block budget <lb/>Block budget <lb/>Yes <lb/>Yes, usually <lb/>Yes, usually <lb/>Yes <lb/>France <lb/>DRG-based payment <lb/>DRG-based payment <lb/>DRG-based payment <lb/>Yes for those requiring a stay in <lb/>hospital <lb/>No <lb/>No <lb/>Public hospital: Yes <lb/>Private hospital: No <lb/>Germany <lb/>DRG-based payment <lb/>DRG-based payment <lb/>DRG-based payment <lb/>Yes <lb/>In part <lb/>In part <lb/>Specialist not hospital-based but <lb/>authorised to practise in a <lb/>hospital: No <lb/>Locums: Yes <lb/>Greece <lb/>DRG-based payment <lb/>DRG-based payment <lb/>Fee-for-service payment <lb/>Yes <lb/>Yes, usually <lb/>Yes, usually <lb/>Public hospital: n.a. <lb/>Private hospital: No <lb/>Hungary <lb/>DRG-based payment <lb/>DRG-based payment <lb/>Fee-for-service payment <lb/>Yes <lb/>No <lb/>No <lb/>Yes <lb/>Japan <lb/>DRG-based payment <lb/>DRG-based payment <lb/>n.a. <lb/>No <lb/>In part <lb/>In part <lb/>Yes <lb/>Netherlands <lb/>DRG-based payment <lb/>DRG-based payment <lb/>n.a. <lb/>Yes <lb/>In part <lb/>No <lb/>Yes <lb/>Poland <lb/>DRG-based payment <lb/>DRG-based payment <lb/>DRG-based payment <lb/>Yes <lb/>Yes <lb/>Yes, but cost of use only, <lb/>not purchase cost <lb/>Yes <lb/>Slovenia <lb/>DRG-based payment <lb/>DRG-based payment <lb/>DRG-based payment <lb/>Usually: part of the care provided in <lb/>day care hospitals is paid for out of a <lb/>global budget <lb/>No <lb/>Yes <lb/>Yes <lb/>Switzerland <lb/>DRG-based payment <lb/>DRG-based payment <lb/>DRG-based payment <lb/>No <lb/>Yes <lb/>Yes, with exceptions <lb/>Yes <lb/>USA <lb/>DRG-based payment <lb/>DRG-based payment <lb/>Fee-for-service payment <lb/>No <lb/>Yes <lb/>Yes <lb/>No <lb/>Australia <lb/>DRG-based payment <lb/>Fee-for-service payment <lb/>Fee-for-service payment <lb/>No <lb/>Yes <lb/>Yes <lb/>Public patient: Yes <lb/>Private patient: No <lb/>Denmark <lb/>Block budget <lb/>n.a. <lb/>DRG-based payment <lb/>Yes <lb/>Yes <lb/>Yes <lb/>-<lb/>Finland <lb/>DRG-based payment <lb/>Yes <lb/>Yes <lb/>Yes <lb/>-<lb/>Italy <lb/>Block budget <lb/>DRG-based payment <lb/>DRG-based payment <lb/>Yes <lb/>Yes, but most regions <lb/>authorise additional <lb/>payments for a range of <lb/>anti-cancer drugs <lb/>Yes, but some regions <lb/>authorise additional <lb/>payments for a regional list <lb/>of medical devices <lb/>Yes <lb/>Norway <lb/>Block budget <lb/>Block budget <lb/>DRG-based payment <lb/>Yes <lb/>In some cases <lb/>-<lb/>No <lb/>Portugal <lb/>Block budget <lb/>Fee-for-service payment <lb/>Fee-for-service payment <lb/>-<lb/>In part <lb/>-<lb/>Yes <lb/>Sweden <lb/>Block budget <lb/>Block budget <lb/>Block budget <lb/>Yes <lb/>Some excluded by some <lb/>regions <lb/>Some excluded by some <lb/>regions <lb/>-<lb/>United Kingdom <lb/>DRG-based payment <lb/>Fee-for-service payment <lb/>Fee-for-service payment <lb/>Yes <lb/>In part <lb/>In part <lb/>Hospital payments <lb/>Day care included <lb/>Expensive drugs included <lb/>Expensive medical devices <lb/>included <lb/>Payments to private doctors <lb/>included <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>70 <lb/></page>

			<body>ANNEX 2: SETTING THE POINT VALUE IN GERMANY <lb/>DELSA/HEA/WD/HWP(2015)1 <lb/>71 <lb/>Période t <lb/>F <lb/>E <lb/>D <lb/>E <lb/>R <lb/>A <lb/>L <lb/>L <lb/>A <lb/>N <lb/>D <lb/>E <lb/>R <lb/>Insurers&apos; <lb/>representative <lb/>Hospitals <lb/>representative <lb/>Federal <lb/>point <lb/>value <lb/>Negociation <lb/>Période t+1 <lb/>+2.5% <lb/>-1.25% <lb/>Land <lb/>point <lb/>value <lb/>Maximum rate of growth in Land <lb/>point value <lb/>Federal <lb/>point value <lb/>Point value band for <lb/>the Land <lb/>Hospital cost index rate <lb/>Wage index rate <lb/>Federal <lb/>point <lb/>value <lb/>Growth of wages <lb/>+ (1/3 (hospital <lb/>cost index-growth <lb/>of wages)) <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>72 <lb/></page>

			<body>ANNEX 3: FORMULA FOR CALCULATING THE HOSPITAL&apos;S ACTIVITIES CAP AND <lb/>REVENUE IN THE CZECH REPUBLIC <lb/>For 2013, the following formula was used to calculate the activities cap for each insurer-hospital <lb/>pairing. <lb/>CAP REV 2013 = max {min [1.07 × CM red × ITC 2011 ; CM red × TC 2013 ]; CMred × ITC 2011 } <lb/>Where: <lb/>CM red = the regulated case mix for the hospital j and the insurer i is calculated as follows: <lb/>S = coefficient for the changes in the number of people insured by each insurer <lb/>CM = total volume (case mix) <lb/>N = number of cases <lb/>α = 0.2 (Cobb-Douglas function coefficient) <lb/>CM red = min {CM 2011 × 0.95 × S; CM 2013 ; (CM 2013 ) α × (1.05 × N 2013 × (CM 2011 /N 2011 )) (1-α) } <lb/>Assuming that no insured person has changed insurer, the formula implies that the case mix to <lb/>calculate the cap is no greater than 95% of the case mix for 2011. <lb/>This formula is easier to understand if the third term in the function is expressed in another form: <lb/>(CM 2013 ) α × (1.05 × N 2013 × (CM 2011 /N 2011 )) (1-α) = 1.05 (1-α) × N 2013 × (CM 2013 / N 2013 ) α × (CM 2011 /N 2011 ) (1-<lb/>α) <lb/>Transforming the third part of the function in this way means that the formula can be interpreted in <lb/>terms of growth in severity per case between 2011 and 2013, since (CM 2013 /N 2013 ) represents severity per <lb/>case in 2013. <lb/>Next, if severity per case increased by 5% between 2011 and 2013, then: <lb/>(CM 2011 / N 2011 )= (1/1.05) × (CM 2013 /N 2013 ) <lb/>By incorporating this equality into the third term in the function Min, it is clear that: <lb/>(CM 2013 ) α × (1.05 × N 2013 × (CM 2011 /N 2011 )) (1-α) = CM 2013 <lb/>Thus, where growth in severity per case is 5%, the formula becomes: <lb/>CM red = min {CM 2011 × 0.95 × S; CM 2013 } <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>73 <lb/></page>

			<body>By demonstrating this equality, we note therefore that 5% is a threshold above which the third term <lb/>plays a role in setting the reduced case mix. The decree not only achieves control over the rate of growth in <lb/>hospital volumes but also helps protect insurers from upcoding. A cap on average case mix per patient is <lb/>set by the Ministry of Health for each hospital. In 2013, an increase greater than 5% would be deemed too <lb/>high. <lb/>To understand how this works, if severity per case rises by less than 5% then: <lb/>CM 2013 &lt; (CM 2013 ) α × (1.05 × N 2013 × (CM 2011 /N 2011 )) (1-α) <lb/>Thus, where growth in severity per case is less than 5%, the formula becomes: <lb/>CM red = min {CM 2011 × 0.95 × S; CM 2013 } <lb/>Similarly, where severity per case increases by more than 5%, then: <lb/>CM 2013 &gt; (CM 2013 ) α × (1.05 × N 2013 × (CM 2011 /N 2011 )) (1-α) <lb/>Thus, where growth in severity per case is greater than 5%, the formula becomes: <lb/>CM red = min {CM 2011 × 0.95 × S; (CM 2013 ) α × (1.05 × N 2013 × (CM 2011 /N 2011 )) (1-α) } <lb/>The intention in the latter case is to constrain any upcoding that may be performed simply to offset a <lb/>fall in the volume of care delivered. Thus, if the volume of care in 2013 is lower than in 2011, a hospital <lb/>that upcodes to offset that drop will be penalised. If the severity per case increases by more than 5%, then <lb/>the third term in the formula will be taken into account. The third term in the function MIN is an average <lb/>of the cases treated weighted by the severity of cases in 2013 and 2011. <lb/>Once the volume-based cap has been set, a revenue cap is calculated to ensure compliance with the <lb/>expenditure objective. In 2013, the formula for calculating the revenue cap was: <lb/>CAP REV 2013 = max {min [1.07 × CM red × ITC 2011 ; CM red × TC 2013 ]; CM red × ITC 2011 } <lb/>Where <lb/>ITC 2011 = conversion rate for insurer i calculated as follows: <lb/>ITC 2011 = TR TOT2011 /CM TOT2011 <lb/>Where TR TOT2011 = total reimbursement for the hospital in 2011 and CM TOT2011 = total volume for <lb/>2011 (case mix) <lb/>And <lb/>TC 2013 = {(1-K) × [0.8 × ITC 2011 + 0.2 (∑ i=1 to n TC i ; 2011 × CM i ; 2011 /∑ i=1 to n CM i ; 2011 )] + (K × NTC)} <lb/>Where <lb/>K = coefficient set to ensure tariff convergence between insurers and hospitals; in 2013, it was 0.30 <lb/>NTC = the national currency conversion rate (CZK 29 500) <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>74 <lb/></page>

			<body>And (∑ i=1 to n ITC i ; 2011 × CM i ; 2011 /∑ i=1 to n CM i ; 2011 ) represents the average point value in 2011 for a <lb/>hospital. The sum of payments received by the hospital is divided by all insurers (∑ i=1 to n ITC i ; 2011 × CM i ; <lb/>2011 ) by the total case mix billed by the hospital (∑ i CM i ; 2011 ). <lb/>Thus, [0.8 × ITC 2011 + 0.2 (∑ i=1 to n TC i ; 2011 × CM i ; 2011 /∑ i=1 to n CM i ; 2011 )] is a weighted average of the <lb/>rate of currency conversion or point value for insurer i in 2011 and the average currency conversion rate <lb/>for all insurers for that hospital. <lb/>TC 2013 therefore incorporates two convergence factors. A first conversion factor, namely the weighted <lb/>average of the point value paid by insurer i and the point value paid by all insurers. The second <lb/>convergence factor is linked to the presence of parameter K in this equation. Thus, TC 2013 is a weighted <lb/>average of the point value specific to one hospital and one insurer and the point value or currency <lb/>conversion rate at national level. <lb/>In the light of the various parameters outlined above, we can now understand the formula for <lb/>calculating revenue caps: <lb/>CAP REV 2013 = max {min [1.07 × CM red × ITC 2011 ; CM red × TC 2013 ]; CM red × ITC 2011 } <lb/>First, let us explain min [1.07 × CM red × ITC 2011 ; CM red × TC 2013 ]. This formula implies that the <lb/>currency conversion rate in 2013 cannot be greater than 7% of the price paid by the insurer in 2011. Next, <lb/>by analysing the formula, we note that, in any event, the hospital&apos;s currency conversion rate cannot be less <lb/>than in 2011. It will be at least CM red × ITC 2011 . <lb/></body>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>75 <lb/></page>

			<listBibl>OECD HEALTH WORKING PAPERS <lb/>A full list of the papers in this series can be found on the OECD website: http://www.oecd.org/els/health-systems/health-working-<lb/>papers.htm <lb/>No. 77 WAGE-SETTING IN THE HOSPITAL SECTOR (2014) James Buchan, Ankit Kumar, <lb/>Michael Schoenstein <lb/>No. 76 HEALTH, AUSTERITY AND ECONOMIC CRISIS: ASSESSING THE SHORT-TERM IMPACT <lb/>IN OECD COUNTRIES (2014) Kees van Gool and Mark Pearson <lb/>No. 75 COMPARING HOSPITAL AND HEALTH PRICES AND VOLUMES INTERNATIONALLY <lb/>(2014) Francette Koechlin, Paul Konijn, Luca Lorenzoni, Paul Schreyer <lb/>No. 74 MENTAL HEALTH ANALYSIS PROFILES (MhAPS) Scotland (2014) Alessia Forti <lb/>No. 73 MENTAL HEALTH ANALYSIS PROFILES (MhAPs) Netherlands (2014) Alessia Forti, <lb/>Chris Nas, Alex van Geldrop, Gedrien Franx, Ionela Petrea, Ype van Strien, <lb/>Patrick Jeurissen <lb/>No. 72 MENTAL HEALTH ANALYSIS PROFILES (MhAPs) Finland (2014) Pauliina Patana <lb/>No. 71 MENTAL HEALTH ANALYSIS PROFILES (MhAPs) Italy (2014) Alessia Forti <lb/>No. 70 PRICING AND COMPETITION IN SPECIALIST MEDICAL SERVICES – AN OVERVIEW FOR <lb/>SOUTH AFRICA (2014) Ankit Kumar, Grégoire de Lagasnerie, Frederica Maiorano, Alessia <lb/>Forti <lb/>No. 69 GEOGRAPHIC IMBALANCES IN DOCTOR SUPPLY AND POLICY RESPONSES (2014) <lb/>Tomoko Ono, Michael Schoenstein, James Buchan <lb/>No. 68 HEALTH SPENDING CONTINUES TO STAGNATE IN MANY OECD COUNTRIES (2014) <lb/>David Morgan and Roberto Astolfi <lb/>No. 67 MEASURING AND COMPARING WAITING TIMES IN OECD COUNTRIES (2013) Luigi <lb/>Siciliani, Valerie Moran and Michael Borowitz <lb/>No. 66 THE ROLE OF FISCAL POLICIES IN HEALTH PROMOTION (2013) Franco Sassi <lb/>No. 65 ALCOHOL CONSUMPTION AND HARMFUL DRINKING: TRENDS AND SOCIAL <lb/>DISPARIETIES IN OECD COUNTRIES (2013) Franco Sassi (Forthcoming) <lb/>No. 64 MANAGING HOSPITAL VOLUMES: GERMANY AND EXPERIENCES FROM OECD <lb/>COUNTRIES (2013) Michael Schoenstein and Ankit Kumar <lb/>No. 63 VALUE IN PHARMACEUTICAL PRICING (2013) Valérie Paris, Annalisa Belloni <lb/>No. 62 HEALTH WORKFORCE PLANNING IN OECD COUNTRIES: A REVIEW OF 26 PROJECTION <lb/>MODELS FROM 18 COUNTRIES (2013) Tomoko Ono, Gaetan Lafortune and Michael <lb/>Schoenstein <lb/></listBibl>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>76 <lb/></page>

			<listBibl>No. 61 INTERNATIONAL VARIATIONS IN A SELECTED NUMBER OF SURGICAL PROCEDURES <lb/>(2013) Klim McPherson, Giorgia Gon, Maggie Scott <lb/>No. 60 HEALTH SPENDING GROWTH AT ZERO: WHICH COUNTRIES, WHICH SECTORS ARE <lb/>MOST AFFECTED? (2013) David Morgan and Roberto Astolfi <lb/>No. 59 A COMPARATIVE ANALYSIS OF HEALTH FORECASTING METHODS (2012) Roberto <lb/>Astolfi, Luca Lorenzoni, Jillian Oderkirk <lb/>No. 58 INCOME-RELATED INEQUALITIES IN HEALTH SERVICE UTILISATION IN 19 OECD <lb/>COUNTRIES, 2008-09 (2012) Marion Devaux and Michael de Looper <lb/>No. 57 THE IMPACT OF PAY INCREASES ON NURSES&apos; LABOUR MARKET: A REVIEW OF <lb/>EVIDENCE FROM FOUR OECD COUNTRIES (2011) James Buchan and Steven Black <lb/>No. 56 DESCRIPTION OF ALTERNATIVE APPROACHES TO MEASURE AND PLACE A VALUE ON <lb/>HOSPITAL PRODUCTS IN SEVEN OECD COUNTRIES (2011) Luca Lorenzoni and Mark <lb/>Pearson <lb/>No. 55 MORTALITY AMENABLE TO HEALTH CARE IN 31 OECD COUNTRIES: ESTIMATES AND <lb/>METHODOLOGICAL ISSUES (2011) Juan G. Gay, Valerie Paris, Marion Devaux, <lb/>Michael de Looper <lb/>No. 54 NURSES IN ADVANCED ROLES: A DESCRIPTION AND EVALUATION OF EXPERIENCES <lb/>IN 12 DEVELOPED COUNTRIES (2010) Marie-Laure Delamaire and Gaetan Lafortune <lb/>No. 53 COMPARING PRICE LEVELS OF HOSPITAL SERVICE ACROSS COUNTRIES: RESULTS OF <lb/>A PILOT STUDY (2010) Luca Lorenzoni <lb/>No. 52 GUIDELINES FOR IMPROVING THE COMPARABILITY AND AVAILABILITY OF PRIVATE <lb/>HEALTH EXPENDITURES UNDER THE SYSTEM OF HEALTH ACCOUNTS FRAMEWORK <lb/>(2010) Ravi P. Rannan-Eliya and Luca Lorenzoni <lb/>No. 51 EFFECTIVE WAYS TO REALISE POLICY REFORMS IN HEALTH SYSTEMS (2010) <lb/>Jeremy Hurst <lb/>No. 50 HEALTH SYSTEMS INSTITUTIONAL CHARACTERISTICS A SURVEY OF 29 OECD <lb/>COUNTRIES (2010) Valerie Paris, Marion Devaux and Lihan Wei <lb/>No. 49 THE CHALLENGE OF FINANCING HEALTH CARE IN THE CURRENT CRISIS (2010) Peter <lb/>Scherer, Marion Devaux <lb/>No. 48 IMPROVING LIFESTYLES, TACKLING OBESITY: THE HEALTH AND ECONOMIC IMPACT <lb/>OF PREVENTION STRATEGIES (2009) Franco Sassi, Michele Cecchini, Jeremy Lauer and Dan <lb/>Chisholm <lb/>No. 47 HEALTH CARE QUALITY INDICATORS PROJECT: PATIENT SAFETY INDICATORS <lb/>REPORT 2009 (2009) Saskia Drösler, Patrick Romano, Lihan Wei; and <lb/>ANNEX Saskia Drösler <lb/>No. 46 EDUCATION AND OBESITY IN FOUR OECD COUNTRIES (2009) Franco Sassi, Marion <lb/>Devaux, Jody Church, Michele Cecchini and Francesca Borgonovi <lb/></listBibl>

			<note place="headnote">DELSA/HEA/WD/HWP(2015)1 <lb/></note>

			<page>77 <lb/></page>

			<body>RECENT RELATED OECD PUBLICATIONS <lb/>ADDRESSING DEMENTIA – THE OECD RESPONSE (2015) <lb/>DEMENTIA RESEARCH AND CARE: CAN BIG DATA HELP? (2015) <lb/>FIT MIND, FIT JOB – FROM EVIDENCE TO PRACTICE IN MENTAL HEALTH AND WORK (2015) <lb/>MAKING MENTAL HEALTH COUNT: THE SOCIAL AND ECONOMIC COSTS OF NEGLECTING <lb/>MENTAL HEALTH CARE (2014) <lb/>HEALTH AT A GLANCE: EUROPE (2014) <lb/>HEALTH AT A GLANCE: ASIA/PACIFIC (2014) <lb/>OECD HEALTH STATISTICS 2014 (Database available from http://www.oecd.org/health/healthdata <lb/>GEOGRAPHIC VARIATIONS IN HEALTH CARE: WHAT DO WE KNOW AND WHAT CAN BE DONE <lb/>TO IMPROVE HEALTH SYSTEM PERFORMANCE? (2014) <lb/>PAYING FOR PERFORMANCE IN HEALTH CARE: IMPLICATIONS FOR HEALTH SYSTEM <lb/>PERFORMANCE AND ACCOUNTABILITY (2014) <lb/>OBESITY HEALTH UPDATE (2014) http://www.oecd.org/els/health-systems/Obesity-Update-2014.pdf <lb/>(electronic format only) <lb/>OECD REVIEWS OF HEALTH CARE QUALITY – CZECH REPUBLIC (2014) <lb/>OECD REVIEWS OF HEALTH CARE QUALITY – DENMARK (2013) <lb/>OECD REVIEWS OF HEALTH CARE QUALITY – ITALY (2015) <lb/>OECD REVIEWS OF HEALTH CARE QUALITY – NORWAY (2014) <lb/>OECD REVIEWS OF HEALTH CARE QUALITY – SWEDEN (2013) <lb/>OECD REVIEWS OF HEALTH CARE QUALITY – TURKEY (2014) <lb/>CANCER CARE – ASSURING QUALITY TO IMPROVE SURVIVAL (2013) <lb/>ICTs AND THE HEALTH SECTOR –TOWARDS SMARTER HEALTH AND WELLNESS MODELS (2013) <lb/>A GOOD LIFE IN OLD AGE? MONITORING AND IMPROVING QUALITY IN LONG-TERM CARE <lb/>(2013) <lb/>STRENGTHENING HEALTH INFORMATION INFRASTRUCTURE FOR HEALTH CARE QUALITY <lb/>GOVERNANCE (2013) <lb/>WAITING TIME POLICIES IN THE HEALTH SECTOR, WHAT WORKS? (2013) <lb/>HEALTH AT A GLANCE (2013): OECD INDICATORS (2013) <lb/>See http://www.oecd.org/health/healthataglance for more information <lb/>HEALTH AT A GLANCE (2013): OECD INDICATORS (2013) <lb/>See http://www.oecd.org/health/healthataglance for more information <lb/>For a full list, consult the OECD On-Line Bookstore at www.oecd.org, <lb/>or write for a free written catalogue to the following address: <lb/>OECD Publications Service, 2, rue André-Pascal, 75775 PARIS CEDEX 16 <lb/>or to the OECD Distributor in your country </body>


	</text>
</tei>
